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The list of Abbreviations 
ACMG – American College od Medical Genetics and Genomics 
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CMTES – Charcot-Marie-Tooth examination score 
CMTNS – Charcot-Marie-Tooth neuropathy score 
CNS – Central nervous system 
CNV – Copy number variant 
CSA – Cross-sectional area 




CTDP1 – C-terminal domain of RNA polymerase II subunit A 
Cx32 – Connexin 32  
de – Demyelinating 
dHSN – Distal hereditary motor neuropathy 
DI-CMT – Dominant intermediate Charcot-Marie-Tooth disease 
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ENG – Electroneurography 
ENMG – Electroneuromyography 
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GDAP1 – Ganglioside-induced differentiation-associated protein 1  
GJB1 – Gap junction beta 1 
GTF – General transcription factor 
HBV – Hepaitis B virus 
HCV – Hepatitis C virus 
HIV – Human immunodeficiency virus 
HMSN – Hereditary sensory and motor neuropathy 
HNPP – Hereditary neuropathy with pressure palsy 




HSAN – Hereditary sensory and autonomic neuropathy 
HSN – Hereditary Sensory Neuropathy 
HSP – Hereditary spastic paraplegia 
in – Intermediate 
INF2 – Inverted Formin 2 
IVIg – Intravenous immunoglobulins  
LDH – Lactate dehydrogenase 
MADSAM – Multifocal acquired demyelinating sensory and motor neuropathy 
 MAG – Myelin-associated glycoprotein precursor 
MFN2 – Mitofusin 2 
MGUS – Monoclonal gammopathy with uncertain significance 
MIRAS – Mitochondrial recessive ataxia syndrome 
MLPA – Multiplex ligand probe assay 
MME – Membrane metalloendopeptidase 
MMN – Multifocal motor neuropathy 
MNCV – Mean nerve conduction velocity 
MRC – Medical Research Council 
MRI – Magnetic resonance imaging 
mtDNA – Mitochondrial deoxyribonucleic acid 
NADH – Nicotinamid adenine dinucleotide 
NCS – Nerve conduction study 
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NDRG1 - N-myc downstream regulated 1 
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NGS – New generation sequencing 
NMD – Neuromuscular disorder 
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p.s. – Present study 
P/F – Patient per family ratio 
P0/MPZ – Myelin protein zero 
PCR – Polymerase chain reaction 
PEO – Progressive external ophtalmoplegia 
PMP22 – Peripheral myelin protein 22 
PNS – Peripheral nervous system 
POLR2A – RNA polymerase 2 subunit A 
qPCR – Quantitative polymerase chain reaction 
RFLP – Restricted fragment length polymorphism 
RLS – Roussy-Lévy syndrome 
RNA – ribonucleic acid 
SANDO – Sensory ataxia neuropathy dysarthria and opthalmoplegia 
SAP – Sensory action potential 
SLE – systematic lupus erythematosus 




SMN1 – Survival of motor neuron 1 
SNP – Singe nucleotide polymorphism 
SNV – singe nucleotide variant 
SPSMA – Scapuloperoneal spinal muscular atrophy 
SPTLC1/2 – Serine palmitoyltransferase, long chain base subunit 1/2 
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Peripheral neuropathy is a term for a group of conditions in which the peripheral nerves 
are damaged. Nerve damage can impair the muscle strength, the sensation, and different 
organ functions. In general, peripheral neuropathies can be classified according to the (i) 
number of affected nerves – mononeuropathy (one), multifocal neuropathy (multiple) or 
polyneuropathy (numerous nerves); (ii) pattern of impairment – symmetric or asymmetric 
(iii) type of involved nerves – motor, sensory or both types of nerves; (iv) type of nerve 
lesion – demyelinating, axonal or mixed, and (v) course of neuropathy – acute or chronic 
condition (1).  
Numerous nerves are damaged in polyneuropathy at the same time resulting in broad 
spectrum of clinical symptoms. Length-dependent nerve degeneration causes the first 
symptoms in limbs, spreading proximal and worsening progressively. Common causes of 
polyneuropathy are (i) diabetes, (ii) alcohol abuse, (iii) infection or (iv) drug related nerve 
damage while other possible etiology with a lower incidence can be (v) tumors, (vi) 
metabolic and (vii) autoimmune diseases or (viii) hereditary disorders (1). 
Hereditary neuropathies are chronic conditions affecting symmetric the motor and/or 
sensory nerves. It is one of the most common inherited neurodegenerative disorders, 
affecting approximately every one person from 2500 (2). The relative homogenous 
clinical appearance of the disease is associated with an especially wide genetic 
background. Charcot-Marie-Tooth disease is the eponym of hereditary motor and sensory 
neuropathy but related disorders – hereditary distal motor neuropathy (dHMN) and 
hereditary sensory neuropathy (HSN) – are also considered as subgroups of CMT (3, 4).  
The expanding knowledge about hereditary neuropathies has broken with the previous 
conventions and indicated more recent perspectives in the last two and half decades.  
Because of the extensive size of the topic and the scarce extent of the space, figures, flow 
charts, and tables are welcomed to use for detailed and easily understandable 




1.1 Historical overview  
The first descriptions of the inherited distal muscle weakness and wasting, calling it 
peroneal muscular atrophy, have been reported by Jean Martin Charcot with Pierre Marie 
and by Howard Henry Tooth in 1886, separately (5). Later, Johann Hoffman described a 
histological finding of thickened nerves in a case with peroneal muscular atrophy in 1912 
(6). From this point, the disorder is also referred as Charcot-Marie-Tooth-Hoffmann 
disease.  
In 1888, Herringham, ahead of his time, has observed a family in which only males were 
affected supposing a distinct genetic feature between males and females (7). In the 
following century, the existence of X-linked inherited neuropathy has been questioned by 
Harding (8); however, it has been later ascertained that the X-linked dominant form of 
CMT (CMTX1) is the second most common genetic cause of hereditary sensorimotor 
neuropathies. Eponyms, like Roussy-Lévy syndrome (RLS) and Déjerine-Sottas 
syndrome (DSS), has become obsolete in the last decades as well, after the genetic 
analyses have proved the same genetic background with CMT (9-13). In spite of that, 
Hereditary Neuropathy with Pressure Palsy (HNPP) has a distinct genetic cause and 
different clinical features than CMT so HNPP is still considered as an independent entity 
among hereditary motor and sensory neuropathy (HMSN) (14). 
Nerve biopsy and pathological diagnosis meant to be the main diagnostic approach in the 
early decades of the 20th Century. Since the late 1970s, electroneuromyography (ENMG) 
has become a ubiquitous diagnostic tool providing new frontiers of non-invasive 
diagnosis, classification and efficient follow-up of hereditary and other neuropathies (15). 
Recently, nerve ultrasound and magnetic resonance imaging seem to be a new trend to 
assign the need for genetic testing, further improving the diagnostic algorithm of 
neuropathies and also proved their reliability in follow-up studies (5).  
The genetic era has officially begun in 1991 with the identification of the first disease 
causing genetic variant in the PMP22 gene (16). Since that time, the research has been 
accelerated and it is still at a bold pinnacle of discoveries of novel genes and genomic 
mechanisms [Fig. 1]. Until now, more than 90 genes have been related to hereditary 




of next generation sequencing started in 2009 which provided a decent catalyst for novel 
findings (4). 
 
Fig. 1 A: The diagram indicates the extension of the literature related to Charcot-Marie-
Tooth neuropathies in the previous decades. The number of publication (y axis) was 
determined by using the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/). Data 
are visualized in five years divisions from 1981 to 2015 and they are arranged in 
chronological order (x axis). B: The diagram shows the number of discovered genes per 
year related to hereditary neuropathy (y axis) since 1991. The number of genes is showed 





The classification of hereditary neuropathies had undergone numerous changes 
depending on the prevailing views about the disease. The first subsets were based on the 
clinical description of the disease, usually used their eponyms for naming them. The 
expanding knowledge and the novel diagnostic possibilities have later required new 
approaches leading to further reconsideration of the actuel classificiations. Nowadays, the 
genetic classification is reckoned as the most sophisticated way of categorization but this 
detailed subdivision is quite a challenge in the daily practice (1) [Table 1, Suppl. 1]. 
Table 1. The different classifications of hereditary motor and sensory neuropathies since 
the first descriptions. Notes: a: it has been first introduced by Dyck and revised by 
Thomas and Harding in 1980 (17); b: The nerve conduction velocity (NCV) of the 
intermediate form is also referred to 30-40 m/s. Mixed pathological findings should be 
also a cirterion (18).  
Original descriptions of 
inherited neuropathies 
According to the clinical and 
pathological features along with the 
inheritance pattern (from 1968) a 
According to the 
nerve conduction 






(peroneal muscular atrophy) 
HMSN type I 
(autosomal-dominant form with low 
conduction velocities and segmental 










severe and early onset 
hypertrophic neuropathy 
with CSF protein elevation) 
HMSN type II 
(autosomal dominant form with 
normal nerve conduction velocities 
and amplitude-reduction while nerve 
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(autosomal recessive form of 
hereditary motor and sensory 
neuropathies) 
HSAN and dHMN 
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Pressure Palsy  
(focal neuropathy in 
predilection spots) 
HMSN type V 







HMSN type VI and VII 
(HMSN with optic atrophy and/or 
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(depending on the severity of motor or 







In addition, the genetic classification of CMT2 has reached and overcame the physical 
barriers of alphabets, therefore, its modification or expansion needs to be considered as 
well.  
All the classification are presently used in different combinations to describe the disease 
accurately. Determining of genetic etiology is not always possible and genetic testing 
needs to be designed carefully. Prior the testing, multiple factors should be taken into 
account: (i) patient’s phenotype (ii) country-specific genetic epidemiology data, (iii) 
availability of genetic screening, (iv) methodology, (v) aim of genetic testing (differential 
diagnostics, preconception, presymptomatic or prenatal counseling, therapy etc.) (1, 4). 
  
1.3 Symptoms and signs 
Charcot-Marie-Tooth neuropathy affects fundamentally both the motor and sensory 
nerves. It is characterized by length dependent nerve degeneration which slowly 
progresses with time leading to worsening of the condition and a gradually developing 
disability (19). It starts usually in the first three decades of life (20).  
The symptoms of classical phenotype occur primarily in the areas of the nerve damage. 
Classical phenotype is characterized by distal muscle weakness (impaired tip toe and heel 
walking, paretic gait, difficulty using zippers and buttons as well as clumsiness in 
manipulating small objects), muscle atrophy (inverted champagne bottle appearance due 
to the loss of muscle bulk), hypotonia, reduction or abolition of tendon reflexes, distal 
sensory loss (e.g. paresthesia, hypoesthesia, anesthesia, sensory ataxia or pain) and often 
associated with fasciculation, cramps or orthopedic deformities, such as hollow feet, foot 
drop, scoliosis etc. [Fig. 2] (1, 19). The disease leads slowly and gradually to impaired 
mobility in most patients but they remain ambulatory supported by orthesis ofirst threer 
walking cane while wheelchair-dependency is infrequent and become required generally 
after the fourth decade of life (21). Pupils may have problems with handwriting in schools 
(22). 
Associated features occur frequently due to the complex physiological roles of different 
CMT genes resulting in atypical signs and symptoms and leading to difficulties in 




symptoms are present, it can inflict overlapping phenotypes with spinal muscular atrophy 
(SMA), hereditary spastic paraplegy (HSP), amyotrophic lateral sclerosis (ALS), 
autosomal dominant optic atrophy (ADOA), ataxias or mitochondrial disorders (4). 
Overlapping phenotypes lead to overlapping pharmacotherapies which further emphasize 
the importance of genetic profiling in the near and distant future. 
 
Fig. 2 27 -year-old male patient harboring the entire deletion of the coding region of 
GJB1 gene. The patient above has moderate sensomotoric neuropathy with a CMTNS 
of 11/36. The photos were taken by the authors. Patient has consented to take the 
photographs and to press them. 
A: inverted champagne bottle appearance due to the loss of muscle bulk while 
proximal musculature is spared; B: pes cavus and atrophy of the small foot muscles; 
C: atrophy of the small hand muscles and deformation of the fingers. 
 
1.4 Genetic background 
Until now, more than 90 genes are known to be related to Charcot-Marie-Tooth disease 




physiological functions of neuronal cells, i.e. (i) myelin proteins; (ii) cytoskeleton, 
nucleoskeleton and nuclear envelope; (iii) transcriptional regulation (iv) protein 
biosynthesis; (v) protein modification, folding and degradation (vi) intracellular transport; 
(vii) ER membrane shaping; (viii) mitochondrial dynamics; (ix) mitochondrial energy 
production; (x) sphingolipid biosynthesis; (xi) phosphoinositide metabolism; (xii) Rho 
GTPase signaling; (xiii) interaction with the extracellular environment (xiv) ion channels 
and (xv) others [Fig. 3] (23). 
 
Fig. 3 Functions of proteins encoded by different CMT associated genes (23). 
Depending on the causative CMT gene, inheritance can be autosomal dominant or 
recessive, or X-linked dominant or recessive. Interestingly, few genes show recessive and 
dominant inheritance, as well (19). Different genes cause a different type of neuropathies 







Fig. 4 The figure demonstrates the overlap of clinical and electrophysiological features 
along with the genetic classification of HMSN without a claim to completeness. It is 
worth to note that some of the genes (MFN2, MPZ, HSPB1, EGR2 etc.) can be categorized 
differently which further complicate the classification (5). 
The four most frequent causative genes are PMP22, GJB1, MPZ and MFN2 in order and 
these are responsible for 70-90 percent of all CMT cases (24). The frequency of major 
and minor genes varies widely in different cohorts and because of the founder effect, 
some of the genetic variants are mainly specific for a certain ethnicity or geographical 
area. Because of the high number of CMT genes, this paper is not suitable for a detailed 
enumeration of genes, therefore, we discuss here the actually studied part of CMT 
genetics (2.4.1. and 2.4.2). Further genes are collected in the supplement (Suppl. 1). 
The expanding number of clinical data have proved the heterogeneity of the appearance 
of CMT. Natural histories of patients varies greatly even in families with same mutation. 
This is especially true in GJB1 families where females tend to have milder phenotypes 
than males [24]. High number of potential modifying factors, such as gene-gene 
interactions, mutation load, epigenetic modification effects, co-morbidities or disease 
management, likely have an impact on its characteristics and leads to a less predictable 
disease progression (25-29). Recently, extensive genotype-phenotype meta-analyses 
studied the possible correlation between various symptoms, disease severity and genes 
(30, 31). It is well known that progression of neuropathy is linked to age but its dynamics 
and age of onset vary widely. It worth to note that around seventy percent of CMT starts 




Depending on the causative gene, additional features can occur in CMT as well. Signs of 
chronic pyramid tract involvement, spasticity, nystagmus or ataxia are sensitive markers 
for MFN2 and GJB1 mutations (33, 34). Hearing impairment is a common feature in 
PMP22, GJB1, MPZ, NDRG1 neuropathies (35-38). Genes, which are involved in 
mitochondrial dynamics (MFN2, GDAP1, DNM2), frequently cause mtDNA deletion or 
depletion, optic atrophy or cerebellar ataxia (39-42) while myopathy might be present 
with DNM2 or LMNA mutation (40). The connection between PMP22 duplication and 
immunological abnormalities has been also reported multiple occasions (43, 44). 
Proteinuria, FSGS, and deafness occur together in INF2 mutations (45, 46). Furthermore, 
respiratory difficulties, phonation disturbances, and age at onset can be related to certain 
genotypes as well. For a detailed collection of reported associated features see Suppl. 1. 
1.4.1 Frequent CMT genes 
1.4.1.1 Peripheral Myelin Protein 22 (PMP22) MIM #601097 
Cytogenetic location of PMP22 is on 17p12 chromosome region (MIM #601097). 
PMP22 encodes a myelin structure protein which comprises 2 to 5% of myelin sheet in 
the PNS (47). Although mainly expressed in PNS, PMP22 mRNA expression has been 
also found in CNS. Studies also suggest a potential role in nerve regeneration, Schwann 
cell differentiation, and growth (48).  
In 1991, PMP22 duplication was the first mutation identified in CMT and later its deletion 
was linked to HNPP in 1993 (14). PMP22 gene is functionally not disrupted in eithers so 
gene-dosage effect seems to be the potential explanation for the disorder. Reiter et al 
identified the molecular etiology where they observed the homologous recombination 
event that was responsible for the unequal crossing over causing a deletion and a 
duplication at the same time in two sister chromatids (49). 
PMP22 duplication and point mutations have been linked to CMT1A and CMT1E, 
respectively. CMT1A is the most common cause of hereditary neuropathies (35-45%) 
whereas CMT1E incidence seems to be less prominent (<1%) (50, 30, 51). Symptoms, 
severity, and age of onset in CMT1A vary widely. Molecular genetic analysis has linked 
the gene to Dejerine-Sottas syndrome and Roussy-Levy syndrome as well which should 




starts in a couple of years after birth but some cases can be completely symptomless 
during entire life.  CMT1A is characterized by classic symptoms of demyelinating 
neuropathy but may occur along with tremor, cranial nerve involvement – facial 
weakness, hearing impairment, and vocal cord palsy – or autonomic dysfunction, too. 
CNS may also be affected by nystagmus, pyramidal signs, white and grey matter volume 
reduction or white matter lesions (31). An elevated level of PMP22 protein may trigger 
the immune dysfunction since CMT1A occasionally associate with chronic inflammatory 
demyelinating polyneuropathy (CIDP) and other autoimmune diseases (52).  
1.4.1.2 Gap Junction Protein Beta 1 (GJB1) 
Gap junction beta 1 (GJB1) gene is located in Xq13.1 chromosome region and encodes 
Connexin 32 (Cx32) proteins. GJB1 is a member of connexin protein family (53) which 
form gap junction channels and are involved in the transport of small molecular weight 
substances (<1kDa). A connexin protein contains four transmembrane (M1-M4), two 
extracellular (E1-2), and one cytoplasmic loop domain (IC) [Fig. 5/A]. Six of same 
connexins form a connexon also called hemichannel [Fig. 5/C] which pairs with the 
connexons of adjacent membrane creating gap junction channels [Fig. 5/B]. Due to the 
highly homologous connexin proteins, different connexons can form heterodimer pores 







Fig. 5 (A) Structure of connexin in the membrane. © refers to cysteine rich regions of 
extracellular domains. (B) Hemichannels of adjacent membranes create the gap junction 
channel. (C) The structure of connexon is formed by six homolog connexin molecules 
where the pore in the middle is gathered around by them. Pores can be both opened or 
closed state influenced by current voltage (54). 
Cx32 is localized in many different cell types including central and peripheral nerves, 
hepatocytes, pancreatic and embryonal cells (56). In peripheral nerves, Cx32 is located in 
the paranodal region and the Schmidt-Lantermann incisures of Schwann cells. It has a 
crucial role in maintaining normal myelination in the peripheral nervous system (57, 58).   
Pathogenic mutations of GJB1 cause X-linked dominant form (CMTX1). To date, more 
than 400 GJB1 pathogenic variants have been identified as the cause of CMTX1 including 
CNVs. CMT1X is responsible for 8.3 to 12.8 percent of all CMT cases, and after PMP22 
gene duplication, it is the second most common cause of CMT (59). CMTX1 shows a 
wide spectrum of sensory and motor symptoms, and the nerve conduction studies reveal 
all forms of sensorimotor neuropathy (60). Though CMTX1 is considered to show X-
dominant inheritance, female carriers usually show milder clinical symptoms than males 
with the same genotype (61, 62). Certain GJB1 pathogenic alterations were in association 
with central nervous system involvement and sensorineural hearing loss as well (63-65). 




is also suspected that the mutant protein has a dominant negative effect and suppresses 
the function of other gap junction proteins which would be able to replace them (66, 67). 
Presumably, both pathogenic changes are possible but depending on certain variants (68). 
1.4.1.3 Myelin Protein Zero (MPZ, P0) 
Myelin protein zero (MPZ) gene is located on 1q23.3 chromosome and encodes the major 
structural protein of peripheral myelin sheet and accounts for more than 50% of myelin 
proteins. It expresses only in PNS (69). MPZ mutations may refer to the third most 
frequent genetic cause of CMT, it accounts for 3-7% of all cases (50, 30, 51). 
In 1993, Hayasaka and al identified MPZ as the cause of CMT1B (70). MPZ pathogenic 
alterations can cause a wide spectrum of hereditary neuropathy – it was found in 
association with Dejerinne-Sottas syndrome, Roussy-Lévy syndrome, congenital 
hypomyelinating neuropathy (71). Electrophysiological patterns vary as well, 
demyelinating, axonal or intermediate types can be also recorded with ENG. Cranial 
nerve involvement, pupil abnormalities, skeletal deformities, deafness, cognitive 
impairment, CNS involvement may be associated features, too (31).  
1.4.1.4 Mitofusin2 (MFN2) 
MFN2 is located on 1p36.2 chromosome region which encodes a dynamin homolog 
protein involved in mitochondrial dynamics (72) (MIM #608507). The protein structure 
is similar to GTPase family members, it consists of two transmembrane anchor domain 
(TM1 and TM2), two helical hapted repeat regions (HR1 and HR2), a GTPase domain 
and a very short region in intermembrane space. Both N and C terminal ends are located 
in the intracellular space [Fig. 6]. Major domains are taxonomically highly conserved 
(73). 
MFN2 has a crucial role in mitochondrial dynamics, especially in mediating fusion, but 
it is involved in calcium homeostasis, ER-mitochondrion tethering, axonal transport and 
intrinsic apoptosis as well. These processes are operating from the energy of GTP 





Fig. 6 (A) Gene and (B) protein structure of MFN2 (75, 76). (C) Colors indicate different 
MFN2 regions where  slices represent the number of known mutations in percentages. 
Abbreviations: (A) G1-G4 indicate GTP binding domains. 
MFN2 is expressed by most cells where mitochondria are present although its dysfunction 
leads to disease only in the high-energy demanding tissues such as nerve cells. MFN2 is 
linked foremost to the axonal form of hereditary sensorimotor neuropathies (CMT2A2) 
but optic atrophy (HMSN-VI) and CNS involvement (HMSN-V) can associate as well 
(23). MFN2 mostly inherits autosomal dominantly but recessive pattern has been also 
described (MIM #608507, CMT2A2B). There are more than 110 known pathogenic 
alterations (77) where phenotypic spectrum, expressivity varies widely (31).  
The precise mechanisms are not yet entirely unfolded but more crucial pathways have 
been identified. Overexpression of MFN2 causes a profound formation of mitochondrial 
network whereas gene silencing results in extensive fragmentation of mitochondria (78). 
In lack of fusion, cell cultures have shown decreased mitochondrial respiration and 
apoptosis while embryonal lethality and neurodegeneration were observed in animal 
models (79). MFN2 is also contributing to mitophagy due to PARK2 ubiquitination, 




unnecessary apoptosis or necrosis of nerve cells (80). In MFN2 carrier patients’ fibroblast, 
bioenergetic studies showed mitochondrial coupling defect and an increase of the 
respiration rate linked to complex II (81). 
1.4.2 Less frequent CMT genes 
1.4.2.1 EGR2 (Early Growth Response 2) (MIM 129010) 
EGR2 gene is localized on 10q21.3 chromosomal region encoding a transcription 
regulator protein with 3 tandem zinc finger. EGR2 induces the expression of many 
essential myelin proteins including Cx32, MPZ and MAG where the mutated EGR2 
protein has a dominant negative effect on the proteins above, by lowering their overall 
expression and resulting in neuropathy (82).   
Warner et al identified the first heterozygous mutation of EGR2 in CMT. Later, 
pathogenic alterations were linked to autosomal dominant and recessive forms of DSS 
and CHN, as well (13, 83). The electrophysiological characteristics are primary 
demyelination whereas sural nerve biopsy may show a severe loss of myelinated and 
unmyelinated fibers, onion bulb formation, and focally folded myelin sheaths (13). There 
are less clinical informations about EGR2 pathogenic alterations, since it proved to be 
less frequent in CMT population; however, it is commonly associated  with severe 
phenotype indicating its screening especially in cases where early onset (<12 months), 
rapid progression and premature death (<6 years) is present (84). EGR2 screening should 
be considered in these cases (13). 
1.4.2.2 CTDP1 (C-Terminal Domain of RNA Polymerase II Subunit A, Phosphatase of 
Subunit 1) (MIM 604927)  
The cytogenetic location of CTDP1 is found on 18q23 chromosome region. CTDP1 
encodes a general transcription factor which is essential in RNA synthesis. The protein 
regulates the activity of RNA polymerase II subunit A (POLR2A) with a posttranslational 
modification. CTDP1 makes possible the initiation of gene expression through POLR2A 
dephosphorylation (85). 
First pathogenic alteration has been described in Rudari Vlax Roma patients with a well-
defined syndrome consisted of congenital cataract, facial dysmorphism and neuropathy 




mutation since high carrier rates are present in Roma individuals (~6.9% in Rudari Gypsy, 
0.6% in other Roma tribes and 0.0% in non-Roma people) (87, 86). Independently of 
signs and symptoms, abnormal cell function was observed in each tissue studied (86). In 
addition to demyelinating neuropathy, skeletal deformities, short stature, congenital 
nystagmus, cataract, facial dysmorphism, and impaired visus may be present as well. 
1.4.2.3 NDRG1 (N-Myc Downstream-Regulated Gene 1) 
NDRG1 is localized on 8q.24.22 chromosome region. NDRG1 protein plays a role in cell 
growth and differentiation as a signaling protein shuttling between the cytoplasm and 
nucleus and its expression is especially high in peripheral nerve cells, mainly in Schwann 
cells (88). All the findings indicate the necessity of NDRG1 in nerve cell survival (88).  
NRDG1 mutations cause autosomal recessive hereditary sensorimotor neuropathy named 
as CMT4D or Lom neuropathy after a Bulgarian town. To date, there are only six 
described mutations where the most frequent p.R148X is considered as a founder 
mutation in Wallachian Roma patients (89, 88, 90, 91). The disease is characterized by 
early onset neuropathy (<10 ys), distal paresis and atrophy, sensory impairment including 
hearing loss, and skeletal deformities (92). Nerve biopsy reveals hypertrophic onion bulbs 
with partial ensheathment of axons, and ENG shows demyelinating type of neuropathy 
(93).  
1.5 Evaluation of the hereditary neuropathies 
Finding the cause of neuropathy is not always easy. A considerable amount of cases stays 
unsolved after excluding all the treatable disorders. Basically, there are two types of 
diagnostic approach – pragmatist and completist. Doctors, who are pragmatists, are 
aiming at minimal possible diagnostic tests to reveal the cause. Other doctors, the 
completists, try to investigate each possibility, even if it may not have a therapeutic 
application. These doctors are usually working in tertiary centers as experts of the field 
(94). 
1.5.1 Clinical assessment 
The medical history should be always carefully recorded. Clinicians should ask about age 




neurotoxic substances (alcohol, chemotherapeutics, medications, toxins etc.), various 
infectious diseases (Lyme disease or tick bite, HIV, HCV, HBV) and other medical 
conditions (malignant neoplasm, lymphoma, multiple myeloma, amyloidosis, 
autoimmune disease, thyroid dysfunction, trauma, uremia etc.) (1) [Fig. 7] 
The routine neurological examination should be performed thorough. To follow the 
progression, the weakness of muscles (e.g. using MRC scale) and the type and area of 
sensory involvement should be given exactly by the physician (94). CMT Neuropathy 
and Examination Scores (CMTNS and CMTES) are powerful and quantitative methods 
to determine the disease severity and to follow-up the progression. CMTNS consist nine 
different scores in three groups: symptoms (3), signs (4) and neurophysiology (2). Each 
score is rated from 0 to 4 regarding the severity (0 – normal, 4 – severe) which means a 
maximum possible score of 36 points per individual. Severity is ranked as follows: ≤10 
mild, 11-20 moderate, >20 severe. CMT examination score can be used as well which 
exclude the scores of nerve conduction study thus the maximum possible score is 28 
points in this case (95). CMT Pediatric Score is designed for children contenting 11 
different items with a total score of 44 (96). These measurements are based on Rasch 
methodology which provides a linear evaluation of progression and follow-up (97). The 
6-min walking test is helpful in measuring walking capability and stamina, and prolonged 
ambulation test can be performed with StepWatch™ medical device (98). 
Laboratory investigation helps to rule out the acquired causes of polyneuropathy and  the 
following lab parameters are advised to check routinely: serum glucose, calcium (Ca2+), 
creatinine kinase (CK), lactate dehydrogenase (LDH), thyroid stimulating hormone 
(TSH), immunoglobulins and B12 vitamin levels, sediment rate; and if it is suspected: 
anti-nuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA), 
ganglioside profile,  immunoglobulin electrophoresis, postinfectious panel (Borellia 
burgerdorfii, human immunodeficiency virus (HIV), hepatitis B and C viruses (HBV and 











1.5.2 Nerve conduction study 
Nerve conduction study (NCS) is a rapid, non-invasive and cost-effective method to 
diagnose and follow-up the polyneuropathy. The three different form of neuropathy in 
CMT are demyelinating, axonal and intermediate types. 
Demyelinating neuropathy is characterized by the progressive loss of myelin sheet. 
According Kelly electrodiagnostic criteria for predominant demyelination, findings 
consists at least 3 of the following features (1) prolonged distal latency in ≥2 nerves, (2) 
<60% reduction of motor conduction velocity in ≥2 nerves, (3) prolonged latency of F 
waves as follows: >3ms in arms or >5ms in legs (≥1 nerve), or absence of F-waves in ≥1 
nerve (4) partial motor conduction block of ≥1 nerve. The criterion of CIDP also 
comprises >130% increased temporal dispersion in ≥2 nerves (99, 100).  
Axonal polyneuropathy is considered if no definitive signs of demyelination are present. 
Kelly electrodiagnostic criteria specify it as follows: (1) >90% of normal NCV if CMAP 
amplitude is >30% of normal, and >60% of normal NCV if CMAP is <30% of normal, 
(2) normal or prolonged distal latency in proportion to conduction velocities, (3) normal 
F waves, (4) no conduction block and (5) fibrillation potentials and neurogenic motor unit 
changes. Axonal loss has two basic patterns of motor conduction alteration: (1) sparing 
of few of the fast fibers with severe amplitude reduction and spared MNCV (>50-60 m/s), 
and (2) sparing only few of slowly conducting fibers which cause a moderate mean nerve 
conduction velocity (MNCV) (>35 m/s) and prolonged distal motor latency beside the 
compound muscle action potential (CMAP) amplitude reduction (101).   
The definition and criterion of intermediate neuropathy are frequently controversial in the 
lack of specific electrophysiological protocol. Most recently, Saporta et al considered 
intermediate neuropathy if MNCV is 38-45 m/s in ulnar nerves and CMAP amplitude 
reduction is >0.5 mV. However, making a difference between axonal and intermediate 
types is sometimes hard due to the sparing only of slowly conduction fibers in axonal 
neuropathy (18). 
Certain genes are specific for distinct types of neuropathy but many cannot be 




signs can be also present such as severe temporal dispersion (CMTX1) or conduction 
blocks (HNPP) which may implicate difficulties in differential diagnostic follow-up. 
1.5.3 Nerve biopsy and imaging studies 
In the first part of 20th century, nerve biopsy and histology meant to be the best diagnostic 
approach of CMT. In demyelinating form, moderate to severe reduction in density of 
myelinated fibers, hypermyelination or demyelination, and a high number of onion bulb 
formations can be observed. The axonal form is characteristic of lack, loss, or 
preservation of nerve fibers and signs of regeneration. After identification some of the 
causative genes, clear genotype-phenotype correlations have been found with certain 
histological changes such as focal axonal alterations due to MFN2 and NEFL mutations, 
congenital amyelination in SOX10, EGR2, CTDP1 alterations or tomacula in HNPP (23). 
In the genetic era, nerve biopsy is mainly obsoleted and is required and justified only in 
few cases like suspected diagnosis of CIPD, amyloidosis or small fiber involvement (23). 
Nerve ultrasound is widely used as a differential diagnostic application in evaluation of 
neuropathies. Lately, more studies attempted to describe the characterization of different 
CMT subtypes like CMT1A or CMT1B. Measurement of cross-sectional area (CSA) of 
peripheral nerves was significantly increased in CMT1A, and CSA correlated with the 
disease severity (CMTNS) and peripheral nerve function (102). In CMT1B, increased 
CSA of median and cranial nerves was observed (103). Axonal neuropathy is not 
characteristic for increased CSA based on several cases (102). 
MRI neurography in CMT may reveal hypertrophic roots typically with onion bulb sign 
which represent hypertrophic demyelination (CMT1 and CMT4) and depicting also nerve 
entrapment or impingement occasionally (104-106). In certain cases, some enhancement 
in nerves may be also seen but it is infrequently a prominent feature. Quantity muscle 
MRI based on Dixon sequences and quantitative muscle ultrasound is suitable to measure 
precisely and reliably the thigh and leg muscle atrophy as well as denervation-related 
fatty substitution which is held as the most responsive measure available in the monitoring 




1.5.4 Genetic diagnostics 
The development and decreasing price of molecular genetic methodologies have opened 
new frontiers in diagnostics of hereditary disorders. Genetic diagnosis can likely prove 
CMT since positive test confirms hereditary neuropathies even in uncertain cases; 
however, negative test results do not exclude CMT. In the last decade, numerous study 
attempt to define an ultimate strategy of genetic testing but these were partly 
unsuccessful. Each population showed divergent gene frequencies and numerous factors 
biased its universal application so these should be considered more likely as a rule of 
thumbs [Fig. 8] (51, 27).  
Recently, new generation sequencing (NGS) lifted to a new level of diagnostic 
perspectives in hereditary disorders. Specific CMT panels may reveal other possible 
genetic modification factors which potentially contribute in the different biological 
pathway and modulate the penetrance and/or the expressivity of the overall phenotype. 
However, the absolute cost of NGS is still high and the quality and reliability of results 
are occasionally questionable. Even today, Sanger sequencing and MLPA are held the 
gold standards in SNV’s and CNV’s analyses despite their limited output but high fidelity 
and feasibility (109). 
In regard to the inheritance, the four most common genes can be advised for analyzing 
before any more extensive screening: in CMT1 PMP22, GJB1, and MPZ, and in CMT2 
GJB1, MFN2, and MPZ in order, based on the following scheme (51). 
 
Fig. 8. A decision tree of successive analysis of suggested genes in CMT (51). 
no male to male 
transmission 





1.6 Management of hereditary neuropathies 
1.6.1 Genetic counseling 
Since the patients’ genetic diagnosis is irrevocable during his/her entire life, genetic 
counseling has an enormous liability in the management of hereditary disorders such as 
CMT. The process of genetic counseling is dedicated to inform the patient about the 
purpose and possible outcomes of genetic testing just as about the expected psychological 
and physical burdens of the diagnosis and how can it affect the offsprings and other 
relatives (110).  
The Hungarian Parliament enacted the state law about human genetics in 2008 (2008. évi 
XXI. törvény) which determine the major points of genetic counseling, testing, and 
research. Even so, in absence of implanting regulations (31.§), some crucial details of its 
execution are still undefined thus fundamental medical consensus and best practice 
should be supreme in these cases. 
Major points of genetic counseling by the law: 
 A patient, who has the capacity, owns the right for a private counseling. 
 Patients must be informed about the purpose of testing, potential consequences, 
methods of processing and storing the genetic material, and data protection, and 
possible benefits and disadvantages of refusal, (6.§ (2)). 
 Genetic counseling is necessary before and after a genetic testing (6.§ (2)). 
 Prognosis, therapeutic possibilities must be communicated and psychological 
support must be offered in appropriate cases (6§ (4)). 
 Patients have the freedom to know or not to know the genetic result (6.§ (7)). 
 The genetic result must not be shared with a third party unless in possession of a 
permission document representing conclusive evidence, or in a case of potentially 
affected family members with clinical relevance (conception, prevention, therapy, 
etc.) related to the result (7.§) 
 Patients must give their written informed consent before sample is taken (8.§) 
Although Charcot-Marie-Tooth disease does not affect the life expectancy in general, 




pretest counseling). Here, the clinicians need to be more prudential regarding the potential 
impact of diagnosis, benefits, and disadvantages. The freedom to not know of the genetic 
result must be kept in sight. Every case is unique and requires experience in leading the 
patient to the right choice. The councelor has to evaluate the possible impact and may 
evade the telling of diagnosis but always the patient decides finally.  
Very important that presymptomatic screening is strictly forbidden and unethical under 
the age of legal competence unless its necessity proved vital regarding a close relative 
(111).  
Another relevant question is the person of the counselor. In absence of implanting 
regulations, the law does not specify who can provide genetic counseling. Reckon with 
the fundamental principle of the law, best practice and medical ethics, no other 
professional should give a genetic counseling but a trained medical doctor with extensive 
knowledge of the field, otherwise the right to information (6.§ (2)) can be easily 
compromised.   
1.6.2 Therapy and treatment 
Until now, no effective treatment was developed in CMT although there are some efforts 
to moderate the overall disease burden. It is very important staying active and keeping up 
the strength with physiotherapy or regular exercises (112). Occupational therapy can help 
in coping with daily tasks (113). Orthoses, orthopedic shoes or canes can support the 
walking and orthopedic surgeries can correct the feet deformities and Achilles 
contractures if needed (114). 
Many promising compounds are in different phases of drug research. PXT3003, which is 
a combination of naltrexone, baclofen, and sorbitol, is currently in phase III 
(NCT02579759). The encouraging results of the animal model showed its beneficial 
effect in lowering PMP22 overexpression (115). Downregulation of PMP22 with 
progesterone antagonist (ulipristal-acetate) is right in phase II (NCT02600286) (116). 
There are novel efforts as well aiming the gene silencing of PMP22 by lowering its 
expression with antisense oligonucleotides and small interfering and hairpin RNAs (117). 




stable Cx32 proteins were produced and maintained in treated Gjb1-knocked out mice 
(118). L-serine supplementation is promising in SPTLC1-2 defects (NCT1733407) (119). 
1.6.3 Avoid of medications 
There is little information about drugs which should be ultimately avoided. 
Unambiguously, neurotoxic medication can progress the neuropathy so the application of 
these drugs should not be used in general. There is a clear evidence that administration of 
vinca alkaloids and taxols may cause rapid and severe progression and nerve injury in 
CMT patients even in mild or asymptomatic CMT (120). In higher percentages of cases, 
nitrous oxide (50%), metronidazole (23%), nitrofurantoin (20%), phenytoin (11%), 
statins (10%) and sertraline (9.5%) can initiate an exacerbation of neuropathy. Other 
drugs have moderate to doubtful risk and should be considered the treatment individually 
and assess the improvement or worsening of disease helping in decision whether benefits 
surpass risks (121).  
1.6.4 CMT and pregnancy 
There are only a few publications about pregnancy risks and CMT and results are 
controversial. A publication from 2012 reviewed the natural history of pregnant women 
with neuromuscular disorders (NMD), including CMT. The study concluded that the 
worsening of status was present in 31% which did not remit in 22% of patients. Very 
important that CMT did not influence significantly pregnancy outcome, labor and 
delivery, mode of delivery, preterm birth and neonatal outcome (122). Another study 
found that pregnancy with CMT indicated a higher occurrence risk of presentation 
anomalies and bleeding postpartum. The rate of caesarean section was doubled and 
forceps was used three times as often in the CMT group as in individuals without NMD. 






In the last decades, the successive exploration of CMT made the diagnostics more 
successful and exact than ever. Furthermore, numerous studies proved that a well-
characterized population and gene specific epidemiological data can enhance the 
efficiency and lower the costs of diagnostics. In this study, we aimed to investigate 
Hungarian CMT patients, unravel the genetic cause of the disease even in still unsolved 
cases and assess the phenotypical variability and spectrum of different causative genes.  
The aims were the followings: 
1. To estimate the frequency of most common neuropathy genes – PMP22, GJB1, 
MPZ, MFN2, EGR2, CTDP1 and NDRG1 – in an extensive cohort of Hungarian 
CMT patients. 
2. To assess the disease features and atypical signs and symptoms of CMT in this 
cohort and detailed descriptions of the phenotype of novel pathogenic and likely 
pathogenic alterations. 
3. To highlight various genotype-phenotype correlations between different CMT 
subgroups, especially between clinically well-characterized female and male 
CMTX1 patients. 
4. To analyze patient for rare variants with high- throughputgenetic methods and 






3.1 Clinical and electrophysiological characterization of the cohort studied 
531 Hungarian CMT patients were enrolled (242 females and 289 males; mean age of 
39.3±17.6, CI95% (37.78 to 40.76)). All individuals were born in Hungary, whereof 55 
patients (10.4%, CI95% (0.78-0.13)) were likely of Roma origin. Some of the novel 
alterations were tested in 350 healthy control individuals (209 female, 141 male; mean 
age 39.88±14.87; CI95% (38.32 to 41.44)) as well. All individuals were born in Hungary 
and descended from Hungarian ancestors. Written informed consent was obtained from 
all individuals. Molecular genetic analysis was performed for diagnostic purposes in all 
investigated patients. The study was approved by the Ethical Committee of Semmelweis 
University (119/PI/12, 7891/2012/EKU).  
Patients routinely underwent neurological examination. Age of onset and family history 
was taken in all cases by asking about other affected relative and first neuropathy related 
symptoms, respectively. Distal hereditary motor neuropathy (dHMN) and hereditary 
sensory and autonomic neuropathy (HSAN) were excluded as well.  
Nerve conduction studies (NCS) were performed by standard techniques (Dantech 
Keypoint, Denmark) with superficial registration and stimulation of sensory, motor and 
mixed nerves. Routinely investigated nerves: sural sensory, peroneal and tibial motor 
nerve conduction and F-waves, ulnar and median nerves sensory and motor conduction 
inclusive F-waves. Demyelinating neuropathy was diagnosed if the distal latency and/or 
F-latency was prolonged and/or the conduction velocity was reduced. The increased 
temporal dispersion was taken as a sign of demyelination as well. Focal conduction block 
was ruled out. Diffuse amplitude-reduction and no evidence of demyelination indicated 
an axonal loss. Nerve lesion was diagnosed as intermediate type if amplitude-reduction 
was present with decreased nerve conduction velocity but the criteria of primary 
demyelination have not been fulfilled (124). We also categorized patients based on nerve 
conduction velocity exclusively, as follows: NCV of ≤38m/s indicated CMT1 while NCV 
of >38m/s indicated CMT2. Normal values in reference to patients’ height and gender 




Patients were considered to suffer from CMT if the clinical and electrophysiological 
signs of motor and sensory neuropathy were present and the family history revealed 
other affected family members.  First and second degree relatives with similar 
characteristics of neuropathy were considered to carry the same pathogenic variant. In 
sporadic cases, the causes of acquired neuropathy (e.g. metabolic, toxic, inflammatory, 
infectious and tumor associated polyneuropathies) were excluded using extensive 
differential diagnostic workup. Further diagnostic tests or procedures (e.g. additional 
laboratory investigation, audiological evaluation, brain and/or spinal MRI or CSF 
analysis) were performed if required based on the clinical picture. The severity of the 
disorder was assessed using the CMT examination and/or neuropathy score part of this 
retrospectively (125).(124)(123).  
3.2 Genetic testing 
DNA was isolated from whole blood using the QIAamp DNA mini kit (QIAGEN®). 
Quantitative changes in the PMP22 gene was analyzed with multiplex ligation-dependent 
probe amplification assay (MLPA) (SALSA MLPA 33 CMT1 probemix, MRC Holland). 
Copy number variation of the GJB1 gene was screened by real-time PCR methodology 
with SYBR Green (ThermoFisher®) staining. Copy number was determined using the 
ddCt method and compared to human serum albumin. The total coding region of GJB1 
(ENST00000374022, NM_001097642), MPZ (ENST00000533357, NM_000530), 
EGR2 (ENST00000242480, NM_000399), MFN2 (ENST00000235329, NM_014874),  
PMP22 (ENST00000395938,  NM_153321) were analyzed using Sanger sequencing 
with specific primers (Suppl. 3) and compared to the human reference genome using 
NCBI’s Blast® application. Hotspot mutations in CTDP1 and NDRG1 (TaqI) genes were 
tested with the PCR-RFLP (CTDP1-NlaIII, NDRG1-Taq1)  methodology. 
CMT1 patients were first screened for PMP22 duplication. If this was negative, 
successive analysis of the coding region of GJB1, MPZ, EGR2, and PMP22 was 
performed. In CMT2 cases, the sequence of GJB1 was first analyzed followed by MFN2 
and MPZ genes. In both CMT1 and CMT2 patients, GJB1 deletion analysis was also 
performed if other tests did not identify the causative gene. GJB1 was only tested if male 
to male transmission was absent. Patients with likely Roma origin were screened for 




In control cohort novel alterations were also screened with PCR-RFLP: GJB1: c.38 T>A 
- Hpy166II (New England Biolabs® R0616S); c.557 A>G - NciI (New England Biolabs® 
R0196S); c.582 G>C – BmtI (New England Biolabs® R0658S))  
Exome Capture was performed in Miami University, Hussman Institute. The procedure 
was executed according to the manufacturer's protocol. For genomic DNA library 
preparation, TruSeq® DNA Sample Prep Kit v2‐Set A (Illumina) and NimbleGen 
SeqCap EZ Human Exome Library v3.0 Kit exome enrichment (Roche) was used. Crude 
pre‐captured genomic library was analyzed by Agilent 2100 Bioanalyzer 1000 DNA chip 
to assess library quality. It was followed by exome enrichment, preparation of hybridized 
libraries, purification and library quality and quantitative control of qPCR. All library 
pools were sequenced on the HiScanSQ Illumina sequencing platform, using 2 × 95‐bp 
pair‐end sequencing protocol, with an extra 9‐bp index sequencing run. 95‐bp paired‐
reads were aligned to the human reference genome (hg19). The alignment was executed 
with Burrows–Wheeler aligner (BWA) software. For variation calling, Samtools software 
was used. We screened genes which are associated with neuropathies and likely involved 
in homeostasis of peripheral neurons. This gene set was compilated based on UNIPROT, 
NextProt, OMIM, and NCBI databases (Suppl. 3.). The variants were checked in Clinvar, 
dbSNP and Ensembl database. We focused on non‐synonymous variants, splice acceptor 
and donor site mutations, and short, frame shift coding insertions or deletions (indel).  
Exonic frameshift and stop mutations were considered as damaging. Missense mutations 
were prioritized, which was based on the protein prediction score annotations given by 
Polyphen2, SIFT, MutationTaster and GERP software (SIFT < 0.1, Polyphen2 >0.5 > 3, 
MutationTaster: disease causing). Using ACMG guideline, the pathogenic and likely 
pathogenic variants were confirmed by Sanger sequencing.  
Target sequencing of patients with predominant motor function impairment was 
performed using Illumina MiSeq platform and an in-house compiled Agilent Haloplex 
capture panel of following genes: AARS, AIF1, ALS2, ANG, ASAH1, ATP7A, BICD2, 
BSCL2, C9ORF72, CHCHD10, CHMP2B, DCTN1, DNAJB2, DNMT1, DYNC1H1, 
EXOSC3, EXOSC8, FBXO38, FIG4, FUS, GAN, GARS, GEMIN2, GLE1, HEXA, HEXB, 
HINT1, HSPB1, HSPB3, HSPB8, IGHMBP2, LAS1L, LMNA, MAPT, MEGF10, MT3, 
NAIP, NEFH, OPTN, PFN1, PLEKHG5, PNPLA6, PRDX3, REEP1, SCO2, SETX, 




TRPV4, UBA1, UBQLN2, VAPB, VCP, VIM, VRK1. Bioinformatic algorithm, variant 
calling and variant analys was identical to the exome capture. 
 
3.3 In silico, pathogenicity and statistical analyzes 
In silico analyses were performed with PolyPhen2, MutationTaster and SIFT softwares. 
The significance of detected alterations was checked with HGMD (www.hgmd.cf.ac.uk), 
dbSNP (www.ncbi.nlm.nih.gov/SNP/), ClinVar (www.ncbi.nlm.nih.gov/clinvar/) and 
CMT database (http://www.molgen.ua.ac.be). The nature of novel alterations was 
assessed based on the ACMG guideline. 
The group comparisons were performed with independent sample t-test and Mann 
Whitney U test regarding means. Percentages were compared with Chi square test. p 
values of <0.05 was considered statistically significant. Odds ratio (OR) in case control 
studies and the 95% confidence intervals (CI95%) for proportions and means were 







4.1 Clinical and electrophysiological assessment 
From the 531 studied CMT patients, 409 (77.0% (CI95% (0.734 to 0.805)) were classified 
as CMT1 and 122 (23.0% (CI95% (0.194 to 0.265)) as CMT2. Family history was 
positive in 148 cases (51.0% CI95% (0.453 to 0.568)) while 142 patients (49.0% CI95% 
(0.433 to 0.548)) were sporadic. The inheritance pattern was autosomal dominant in 123 
cases with a mean patient per family ratio (P/F) of 2.6. X-linked dominant and autosomal 
recessive inheritance were present in 13 (P/F: 3.4) and 12 (P/F: 1.8) cases, respectively.  
CMTES and CMT related additional features could be assessed in 309 cases (58.2% 
CI95% (0.540-0.624)). The mean CMT examination score was 8.9±4.3 (CI95% (8.42-
9.38), with a minimum of 0 and a maximum of 22. Symptoms began before the age of 30 
in 69.3% of CMT cases; however, the age of onset ranged between the first and seventh 
decade of life. Additional features were found in a total of 22.3% of  patients (CI95% 
(0.177-0.270)) as follows: CNS involvement in 7.8% (24), facial, glossopharyngeal and 
recurrent laryngeal nerve palsy in 5.2% (9, 4 and 3 respectively), bilateral sensorineural 
hearing impairment in 4.9% (15) (<40 dB and age at onset <40 years),  immune 
dysfunction in 2.9% (9), autonomic nervous system (ANS) involvement in 1.6% (5), 
cataract in 1.3% (4) and optic atrophy in 0.7% (2) of the cases.  
4.2 Genetic testing and distribution of genetic subtypes 
Within the studied cohort, genetic testing confirmed the causative gene in 276 CMT1 
(67.2% CI95% (0.617 to 0.728)) and in 42 CMT2 (34.4% CI95% (0.260 to 0.428)) 
patients. Altogether 318 CMT patients (59.9% CI95% (0.557 to 0.641)) received a 
genetic diagnosis, while in 213 individuals (40.1% CI95% (0.359 to 0.443)) we could not 
detect any pathogenic alterations within the genes studied. 
Regarding the entire CMT cohort, the most frequent causative gene alteration occurred in 
PMP22 (40.1%) followed by GJB1 (9.6%), MPZ (4.5%), MFN2 (2.4%) NDRG1 (1.5%), 
EGR2 (0.8%) and CTDP1 genes (0.8%) [Table 2]. Homozygous founder mutations in 
NDRG1 and CTDP1 genes were present in 21.8% of investigated Roma patients, with 





Table 2 – Pathogenic and likely pathogenic variants identified in the studied cohort and 

























PMP22 c.353 C>T T118M pathogenic 1/2 CMT1 male second mild 
(127, 
128) 
GJB1 c.38 T>A V13E 
likely 
pathogenic 
1/2 CMT2 male second severe (129) 
GJB1 c.43 C>T R15W pathogenic 1/1 CMT1 male first moderate (130) 
GJB1 c.187 G>A V63I pathogenic 1/2 CMT2 male second moderate (131) 
GJB1 c.224 G>A R75Q pathogenic 2/5 CMT1 male/female second moderate (132) 
GJB1 c.265 C>G L89V pathogenic 1/2 CMT1 male second severe (133) 











I127V pathogenic 1/3 CMT1 male second moderate p.s. 
GJB1 c.425 G>A R142Q pathogenic 1/2 CMT1 male first severe (136) 
GJB1 c.490 C>T R164W pathogenic 1/1 CMT1 female first mild (137) 
GJB1 c.491 G>A R164Q pathogenic 1/3 CMT1 male first severe (138) 
GJB1 c.514 C>G P172A pathogenic 1/4 CMT2 male second severe (139) 
GJB1* c.557 A>G E186G 
likely 
pathogenic 
1/4 CMT2 male third moderate (129) 
GJB1* c.582 G>A M194I 
likely 
pathogenic 
1/3 CMT1 male second mild (129) 
GJB1 c.614 A>G N205S pathogenic 1/3 CMT1 male first moderate (136) 
GJB1 c.623 G>A E208K pathogenic 1/2 CMT1 male second mild (140) 
GJB1 c.712C>T R238C pathogenic 1/2 CMT1 male first moderate (141) 
GJB1 deletion - pathogenic 2/4 
CMT1/ 
CMT2 





4.3 Novel alterations in our CMT patients 
In this study, nine novel mutations have been identified which were present neither in 
literature nor in mutation databases. All of the amino acid changes are located at highly 
conserved protein residues and the in silico analyzes qualified them as disease causing 

















MPZ c.58 T>C S20P 
likely 
pathogenic 
1/4 CMT1 male < 1 year moderate  p.s. 
MPZ c.131 C>T S44F pathogenic 1/4 CMT2 female n/a n/a  (143) 
MPZ c.143 T>C L48P pathogenic 1/6 CMT1 female fourth mild  (144) 
MPZ c.253 G>A G85R 
likely 
pathogenic 
1/3 CMT2 female sixth moderate  p.s. 
MPZ c.284 T>G F95C 
likely 
pathogenic 
1/1 CMT1 female first moderate  p.s. 
MPZ c. 335 T>C  I112T pathogenic 1/3 CMT1 female fourth mild  (145) 
MPZ c.370 A>C T124P 
likely 
pathogenic 
1/1 CMT1 male seventh moderate  p.s 




MFN2 c.314 C>T T105M pathogenic 1/2 CMT2 female first severe  (147) 
MFN2 c.383 A>G H128R pathogenic 1/2 CMT2 female first moderate  (148) 
MFN2 c.839 G>A R280H pathogenic 1/1 CMT2 female second  mild  (149) 






EGR2 c.971 G>A R324H 
likely 
pathogenic 
1/2 CMT1 male second moderate  p.s 
EGR2 c. 1142 G>A  R381H pathogenic 1/2 CMT1 male third severe  (150) 













c. 557 A>G and c.582 G>C as well as MPZ c.58 T>C, c.253 G>A and c.284 T>G – OR: 
5.02, CI95% (0.2 – 123.8), p=0.17) or in the Exom Aggregation Consortium 
(http://exac.broadinstitute.org), in the 1000 Genomes Project (http://1000genomos.org) 
and in the Exome Sequencing Project (http://evs.gs.washington.edu/EVS). According to 
the American College of Medical Genetics and Genomics’ (ACMG) guideline, our newly 
described variants should be considered as likely pathogenic or pathogenic [Table 3]. 
Table 3. Unpublished novel alterations detected in the study cohort.  



































































4.3.1 Clinical description of patients with novel alterations 
MPZ c.58 T>C (p.Ser20Pro) variant 
The Ser20Pro variant was found in a 5-year-old patient with severe neuropathy. Male 




overall clinical picture was SMA like, but neither SMN1 nor dystrophin gene deletion or 
duplication was present.  Familial segregation analysis was not possible in other relatives. 
The proband’s symptoms started at age of 3 months with hypotonic muscles. At age of 5, 
he was not able to sit or walk and his muscles were severely hypotonic. Due to lack of 
cooperation, precise investigation of muscle weakness or sensory impairment was not 
possible. The ophthalmological examination found a pale optic disc and congenital 
nystagmus on both sides. Creatine phosphokinase laboratory test was normal.  
The electrophysiological investigation found severe demyelinating neuropathy with 
moderate amplitude reduction. Sural nerve biopsy revealed profound nerve degeneration 
with both demyelinating and axonal components.  
MPZ c.253 G>A (p.Gly85Arg) variant 
An unknown SNV has been found in a 50-year-old female whose symptoms started in the 
first decade of life with gait disturbance. Longitudinal progression was minimal for 40 
years, however, in the last couple of years, the symptoms notably worsened. She 
mentioned two relatives with neuropathy but more prudent medical history was not 
available. 
Her status indicated moderately severe distal paresis and atrophy where proximal muscles 
were mildly affected. Tip toe and heel walking could not be executed and feet had high 
arches on both sides. No prominent sensory disturbances were detectable. The 
electrophysiological investigation has shown severe sensorimotor demyelinating 
neuropathy with marked amplitude reduction. Since 1986, she has recurrent trigeminal 
neuralgia on the left side and complained about tinnitus as well.  
MPZ c.284 T>G (p.Phe95Cys) variant  
The Phe95Cys likely pathogenic alteration was found in a 75 -year-old female patient 
whose symptoms became definitive at age of 69. Before that, she complained about 
frequent myalgia, muscle cramps and some postural instability for decades. Her mother 





Currently, her gait disturbance progressed so far that she regularly falls and suffers serious 
traumas. Tip toe and heel walking is not possible and she needs help standing up from 
crouch. Hand and feet muscles, dorsal- and plantarflexion are moderately paretic. Loss of 
tactile, algetic, vibration, heat and cold perceptions are present distally and symmetric 
from knee and elbow.  
MPZ c.370 A>C (p.Trp124Pro) variant 
A new MPZ variant was detected in a 75 -year-old male CMT patients whose symptoms 
started at age of 69 with myalgia, limited walking distance and sensory disturbance of 
lower limbs. At the date of examination, his status indicated moderate paresis of dorsal- 
and plantarflexion and feet atrophy, paretic gait, areflexia, impaired tactile and vibration 
perception and spinal ataxia. Both upper limbs were spared from neuropathic symptoms. 
Electroneurography indicated a severe demyelinating neuropathy with seconder axonal 
loss. No affected relatives were mentioned by the proband. 
EGR2 c.971 G>A (p.Arg324His) variant 
A missense nucleotide substitution of EGR2 was identified in a 22 -year-old patient whose 
symptoms started at age of 20 with gait disturbances and multiple ankle subluxation. 
None of his relatives were affected with symptoms of neuropathy. Familial segregation 
analysis was not possible to perform. 
His status indicated mild paresis of both peroneal muscles with normal knee and Achilles 
reflexes. Atrophic quadriceps and spared sensory qualities were present as well. 
Electrophysiological study revealed reduction of nerve conduction but it was more 
pronounced in motor nerves which are congruent with clinical findings. Interestingly, the 
autonomous nervous system was also affected, the patient complained about nocturnal 
enuresis and incontinency where no urological etiology could be explored. 
GJB1 c.38 T>A (p.Val13Glu) variant 
We identified the p.Val13Glu novel amino acid change in a 35 -year-old male patient 
whose symptoms started at age of 15 with gait disturbance and lower limb weakness. Her 
mother (72) suffers from similar but milder neuropathy where genetic analysis confirmed 




Neurological examination of the proband at age of 35 has shown paretic gait, the absence 
of reflexes, paresis, and atrophy of lower and upper limbs – 4/5 and 3/5 in MRC scale, 
respectively. Tactile and vibration loss was present only on the lower limbs under the line 
of knees. ENG has revealed axonal neuropathy while EMG showed neurogenic lesion of 
tested muscles. As atypical signs and symptoms, postural tremor of hands and Babinski 
sign with spasticity of lower limbs were also accompanied to the phenotype. 
His mother’s symptoms started a bit later at age of 26. Her symptoms were less severe in 
spite of her advanced age but she shared her son’s symptoms of paretic gait, weak hands, 
areflexia and sensory disturbance. None of the atypical features were present. 
Interestingly, both patient’s hand were more severely affected with atrophy and paresis 
than feet or upper limbs. 
GJB1 c.379 A>G (p.Ile127Val) variant 
The hemizygous p.I127V alteration in GJB1 was found in a 25 -year-old male whose 
definitive symptoms started at age of 11; however his motor development was little 
delayed and also shown less dexterity in sports and in manipulating small objects. His 
maternal grandfather has severe gait disturbances. 
The neurological status at age of 25 indicated severe motor and sensory neuropathy 
associated with bilateral Achilles contractures, horizontal nystagmus and spasticity. 
Electrophysiological examination at age of 14 has shown axonal polyneuropathy but at 
age of 25 it revealed more intermediate type. Her mother also underwent 
electrophysiological study and neither CMAP reduction nor conduction slowing was 
present. Segregation analysis confirmed the carrier status of the mother. 
GJB1 c.557 A>G (p.Glu186Gly) variant 
The c.557 A>G nucleotide substitution in GJB1 was found in a 47 -year-old male patient. 
His mother, maternal grandmother and his two daughters suffered from a milder form of 
CMT.  
The proband’s symptoms started at the age of 12 with gait disturbances but progression 
started later at age of 25 years. At the age of 47, the severity of paresis and atrophy were 




reflexes were absent, and distal loss of palpation and vibratory sensation on a lower limb 
has been found as well. Electrophysiology has registered severe axonal neuropathy. Sural 
nerve biopsy was also executed where axonal and demyelinating features were 
simultaneously present with thickened nerve, onion bulb formation, and severe axonal 
degradation. His comorbidities included hypertonia, non-ST elevated myocardial infarct, 
and three-vessel coronary disease.  
All the affected relatives were female. There is little information about his mother and 
grandmother but about his daughters. Both daughters were relatively young at the time of 
examination (8 and 12) whose symptoms started under the age of 5 with clumsiness of 
hands and mild paresis in lower limbs with impaired tip toe and heel walking. The 
symptoms not influenced their daily tasks although the elder girl was less able to play 
violin due to the stiffness of hand muscles. ENG indicated an axonal lesion in both 
children. Genetic analysis confirmed the presence of an alteration in both of them. 
GJB1 c.582 G>C (p.Met194Ile) variant 
A novel alteration of GJB1 was also identified in a 23 -year-old male patient who has a 
positive family history. While his mother was symptomless, his maternal grandfather 
suffered from severe neuropathy with wheelchair dependency. 
The proband’s symptoms started at age of 18 years with paretic gait and distal muscle 
weakness of lower limbs. Neurological examination at age of 23 indicated moderately 
severe muscle weakness and atrophy of extremities together with areflexia. The distal 
sensory loss was present on all limbs. Proximal muscle strength and sensory modalities 
were spared. Unusually, cardiomyopathy and accessory electrical conduction pathway 
between left atrium and ventricle were present as well. ENG registration indicated 
intermediate neuropathy as well as prolonged temporal dispersion with 30%. Muscle 
biopsy was also performed where numerous angular fibers were present. In many of the 
fibers targetoid sign was present indicating severe neurogenic alteration. Genetic analysis 
of GJB1 identified a novel alteration [Fig. 9]. Family segregation analysis verified the 
presence of c.582 G>C nucleotide substitution in his mother and maternal grandfather, 




grandfather was affected by very severe neuropathy with a disease onset in the early 
twenties.  
 
Figure 9. Muscle biopsy has shown moderate neurogenic damage with numerous 
targetoid fibers. (A) Hematoxylin-eosin staining with angular fibers (arrow) and a 
prominent difference between fiber diameters (B, C) NADH and mSDH staining show 
the targetoid pattern (central parts of some fibers are clearly lighter stained (arrows), 
which is common is neurogenic atrophy. (D, G) On the semithin sections and on EM 
picttures  numerous vacuoles were present. (F, G) EM pictures have shown myofibrillar 
disorganization with slightly increased mitochondria. 
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4.4 Investigation of the phenotypic spectrum in CMT subtypes 
Age, age of onset and disease duration did not significantly differ between the studied 
subtypes of CMT Males carrying the GJB1 pathogenic alteration had the highest CMTES 
(p<0.01). Female CMTX1 patients, who had the mildest disease burden (p<0.001), were 
frequently symptomless (23.1%, p<0.05) and had a delayed onset of disease (p<0.05) 
[Table 4, Fig. 10]. 
Table 4.The distribution of CMTES, age, age of onset and disease duration in the most 
common genetic subtypes and in the general CMT cohort. 
The Spearman test and linear regression analysis were performed in 
CMT, PMP22, GJB1, MPZ and MFN2 cohorts. There was a positive correlation between 
CMTES and age (<0.05) as well as between CMTES and disease duration (<0.01) in each 
group. No potential association was apparent with linear regression analysis other than a 
moderately weak correlation between CMTES and disease duration [Fig. 10]. CMT1A 
and CMTX1 patients showed a somewhat stronger correlation between disease severity 
and duration. However, it is important to note that the 
MFN2 and MPZ cases represent only a narrow range of the variable, thus the 
extrapolated regression lines are unreliable for making such predictions [Fig. 10].  
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Fig. 10. Statistical analysis of disease progression in different CMT groups.  
The first column represents the number of patients and the age of onset (in decades) while 
the second column shows the regression lines fitted on the scatter plots. Values of scatter 
plots: CMT: r2=0.248, adjusted r2=0.245, p<0.001; PMP22: adjusted r2=0.503, p<0.001; 
GJB1 male: adjusted r2=0.595, p<0.001; GJB1 female: adjusted r2=0.398, p<0.01; MPZ: 
adjusted r2=0.000, not significant; MFN2: adjusted r2=0.024, not significant.  *Dark bars 
and dots as well as the upper regression line indicates the male GJB1 patients. Female 




The frequency of atypical CMT features were also statistically analyzed. Here we list only 
the significantly correlating features and genes.  
Dysimmune mechanisms (6.5%, N=6, 5 unrelated patients) were more frequently 
associated with PMP22 duplication (p<0.01) compared to the non-CMT1A patients. 
Three patients had inflammatory polyneuropathy, as well, where ENG signs of 
conduction block and/or temporal dispersion, elevated liquor protein, immunological 
markers and a good therapeutic response to steroid, plasmapheresis or IVIg indicated the 
diagnosis. One patient with systemic lupus erythromatosus (SLE) also carried a PMP22 
duplication where the polyneuropathy antedated the SLE. Other two patients suffered 
from autoimmune thyroiditis and in one case autoimmune vasculitis was also associated 
with CMT1A. Six patients with NDRG1 mutations had early onset hearing impairment 
(p<0.001), and PMP22 duplication was also commonly present with deafness (6.5%, 
N=6). Hearing impairment of >40 dB, starting before age of 40 indicated the early onset 
hearing impairment cohort of the study. 
The frequency of CNS involvement was higher in MFN2 (50%, N=5) and male GJB1 
patients (37.5%, N=6) (both p<0.01). These two genes were responsible for half of the 
cases with CNS symptoms. In CMTX1, central nervous system involvement and 
pathological MRI findings were present with a male prevalence (males 42%; females 9%; 
p=0.57). One individual suffered from acute episodes of CNS dysfunction accompanied 
by dysphagia, dysarthria and upper limb paresis at the age of 6, 10 and 14 years. Chronic 
corticospinal tract dysfunction was present in one patient who had Babinski sign and 
spasticity in lower and upper limbs. Horizontal nystagmus was observed in one male and 
in one female patient. Brain MRI was available in four CMTX1 cases and two patients’ 
MRI showed (1) increased white matter signal intensity on T2 weighted and FLAIR 
sequences in the right hemisphere, and (2) in the periventricular area on the left side 
without relevant clinical symptoms or history of CNS involvement.  
Interestingly, four from five MFN2 patients with p.R468H mutation (3 female and 1 male, 
mean age of onset: 27.3 ys) showed CNS involvement, although the severity of 
neuropathy was mild in general. A female patient without any classical neuropathic 
feature or electrophysiological changes presented horizontal nystagmus, spasticity, 




prominent cerebellar ataxia with mild sensory involvement, normal muscle strength and 
moderate axonal neuropathy. Two additional cases with p.R468H mutation were 
complicated with spasticity and with a more prominent motor dysfunction than sensory 
loss.  
4.5 Clinical features and gender comparison of a set of patients carrying GJB1 
mutation 
Clinical features of a subgroup of well-characterized CMTX1 patients (12 males and 11 
females – proband and relatives as well; mean age at examination was 36.5±15.4 years 
and 43.8±15.5 years, respectively) showed various classical symptoms characteristic of 





Table 5. Male and female probands’ clinical features of the subset of CMTX1 patients 
studied.  
Abbreviations: AA – amino acid; AoO – Age of Onset, DD – disease duration, NCS – 
nerve conduction study, m – male, f – female, ax – axonal, in – intermediate, de – 




AoO DD NCS 
Upper limb Lower limb 












B-GJB1 m R15T 12 14 in ++ - ++ - 
migraine with 
aura 
C-GJB1 m V63I 11 25 ax ++ + + - - 




E-GJB1 m A96G 36 10 ax ++ ++ +++ +++ - 
F-GJB1 f A96G 49 12 in + ++ + ++ - 
G-GJB1 f R107W 30 10 de + + +++ ++ - 




I-GJB1 f R164W 5 8 in - - ++ + nystagmus 
J-GJB1 m R164Q 9 63 in ++ + +++ + MRI abnormality 
K-GJB1 m P172A 26 27 ax ++ ++ ++ ++ 
postural tremor, 
hepatic lesion  
L-GJB1 m E186G 12 35 ax + + ++ ++ - 











Age at onset was 15.5±8.4 for males and 30.7±16.0 for females (p<0.05). The disease 
duration did not differ significantly between genders, with a value of 21±15.4 in males 
and 14.5±7.1 in females. Females were frequently asymptomatic (total 17%; male 0%; 
females 36%; p<0.05). Distally prominent muscle weakness was the most common 
symptom (total 83%; male 100%; female 64%; p=0.03) which was followed by sensory 
disturbances (total 78%; male 100%; female 55%; p=0.01). The lower limbs were more 
often affected (total 83%; male 100%; female 64%; p=0.03) than the upper limbs (total 




4.5±4.3 for females (p<0.001) while mean CMT neuropathy subscores ranged 1.3 - 2.9 
in males and 0.2 - 0.8 in females)  [Table 6].  
Table 6. This table shows the statistical correlation of CMTX1 phenotype between males 
and females. 
   Male Female p-value 
CMT neuropathy subscores    
Sensory symptoms 2.3±1.1 0.8±0.8 <0.01 
Motor symptoms (legs) 1.8±1.2 0.6±0.7 <0.01 
Motor symptoms (arms) 1.3±1.0 0.2±0.4 <0.01 
Pinprick sensibility 2.0±1.0 0.8±0.8 <0.01 
Vibration 1.8±0.9 0.5±0.7 <0.001 
Strength (legs) 2.9±0.8 0.7±1.1 <0.001 
Strength (arms) 1.9±1.2 0.4±0.5 <0.001 
Ulnar CMAP 2.4±1.0 0.5±1.0 <0.001 
Radial or Ulnar SAP 2.2±0.9 0.6±1.1 <0.01 
Tremor 5 (42%) 0 (0%)  <0.05 
Pes cavus 8 (67%) 2 (18%) <0.05 
Decreased/absent reflexes 11 (75%) 3 (27%) <0.01 
CNS involvement 5 (42%) 1 (9%) not significant 
 
The distribution of probands’ electrophysiological changes was the following: 5 primarily 
axonal (35.7%), 5 intermediate (35.7%), 4 demyelinating (28.6%). The type of 
neuropathy was identical in the same families. ENG features also revealed increased 
temporal dispersion in 5 patients where definite temporal dispersion was found 
exclusively in one patient (>30% at least in two nerves). None of the CMTX1 patients 
reported hearing impairment. 
Previously reported GJB1 cases were also collected and compared with out findings based 




Table 7. Comparision of previously described mutations and our cases. *Axonal type was 
found in younger patients (6 and 8 ys old) while adult patients have shown intermediate 
nerve damage. 
Mutation  Features Patients of this study Reported patients 
Arg15Trp Gender and reference male female (152) 
Age of onset 12 9 
Motoric symptoms 
UL and LL severly affected, 
normoreflexia 
UL and LL severly affected, areflexia 
Sensory symptoms loss of sensation loss of sensation 
Other symptoms  pes cavus pes cavus 
NCS intermediate intermediate  
    
Val63Ile Gender and reference male male (66) 
Age of onset 11 14 
Motoric symptoms 
severe paresis and atrophy of UL, 
mildly affected LL 
UL mildly affected, gait disturbance 
Sensory symptoms - - 
Other symptoms  
- hypacusis,cognitive deficiency, 
nystagmus, pes cavus 
NCS axonal axonal  
    
Arg142Gln Gender and reference male female and male (65) 
Age of onset 6 2-8 
Motoric symptoms atrophy and paresis of LL areflexia atrophy and paresis of LL areflexia 
Sensory symptoms lack of vibration sense lack of tactile and vibration sense 
Other symptoms  - hypacusis 
NCS demyelinating deminalinating and axonal*  
    
Arg164Trp Gender and reference female female and male (153) 
Age of onset 5 2-15 
Motoric symptoms 
increased muscle tone, hypertrophy, 
hyperreflexia 
moderate and severe paresis and atrophy 
of UL and LL, areflexia 
Sensory symptoms - loss of sensation 
Other symptoms  pain, pes cavus, Achilles contracture pes cavus, hypacusis 
NCS intermediate intermediate  
    
Pro172Ala Gender and reference male no data (154) 
Age of onset 26 no data 
Motoric symptoms 
moderate atrophy and paresis of UP 
and LL, hyporeflexia 
distal atrophy and paresis of UL and LL, 
areflexia 
Sensory symptoms deep sensory disturbances  no data 
Other symptoms  pes cavus pes cavus 
NCS axonal axonal  
    
Asn205Ser Gender and reference female and male female and male (155) 
Age of onset 3 13, 19 
Motoric symptoms 
paresis and atrophy of LL, female 
symptomless 
paresis and atrophy of LL, female 
symptomless 
Sensory symptoms hypaesthaesia no data 
Other symptoms  
static hand tremor, pes cavus,  pes cavus, transient CNS involvment 




4.6 Analysis of rare variants with high-througput methodology. 
From the studied CMT2 cohort, 15 well-characterized CMT patients have been analyzed 
– 6 with whole exome sequencing and 9 dHMN-HMSN overlapping phenotype with 
target sequencing – (7 males and 8 females, mean age at examination was 29.5±18.2 years 
and 26±16.5 years, respectively).  In these cases, no pathogenic variants were found in 
the screened genes (PMP22, GJB1, MFN2, MPZ, CTDP1, NGDR1). Through a detailed 
analysis of data, pathogenic or likely pathogenic alterations were found in 5 patients 
(33.3%).  The identified alterations are summarized in Table 8.  
Table 8. List of identified pathogenic or likely pathogenic alterations 
Patient Method Sex Gene Mutation ACMG Reference 
1-CMT WES 
(Centogene) 





WES male MME c.1946T>C  
p.I649T 
VUS p.s. 

















female HINT1 c.110G>C 
p.R37P 
pathogenic (185) 
4.6.1 TRPV4 pathogenic alterations  
The c.806G>A, p.R269H known pathogenic mutation of TRPV4 was indentified with 
whole exome sequencing performed by Centogene AG, Rostock. Raw data of sequences 
were not available for further analysis, only the finding given by the company. 
The alteration was found in a two and half -year-old girl whose symptoms started at age 
of 8 months with clumsiness and delayed motor development. The parturition was 
spontaneous and the perinatal period was uneventful, only congenital club-feet and mild 




paresis (4/5 by MRC scale) and spared tactile and vibratory sensation of all limbs. 
Scapular muscles were not affected and otolaryngologist also excluded laryngeal palsy. 
Her body weight and height were between 25 and 50 percentile and mental development 
was age-appropriate, too. Expect the persisting club-feet, no other orthopedic 
malformation were present. Electrophysiological investigation revealed a severe 
reduction of CMAP amplitude in peroneal, tibial ulnar and median nerves. SAP amplitude 
reduction of sensory nerves were minimal. NCV was spared of all nerves. Both parents 
have not shown any clinical or electrophysiological signs of neuropathy and genetic 
analysis proved that they do not carry the TRPV4 alteration.  
4.6.2 POLG and MME likely pathogenic alterations  
A 35 -year-old patient was analyzed with whole exome sequencing. Cavus feet were 
present since early childhood but definitive symptoms started at age of nine with gait 
disturbances. At the time of neurological examination he had moderate distal muscle 
weakness which was more pronounced in lower than in upper limbs. (4-/5 and 4/5 by 
MRC scale, respectively). Below the line of knee and wrists, the sensory functions were 
also deprived. He also barely recognized somatosensory stimuli in these areas. 
Electrophysiological evaluation revealed axonopathy of motor, sensory and mixed nerves 
with spared nerve conduction velocities. It seems to be a sporadic case but the patient has 
minor twins (7 ys old) who are symptomless. Genetic analysis of parents and offsprings 
was not possible.  
Exome capture sequencing generated ~8.9 billion bases of sequence, and ~8.7 billion 
bases were then mapped to the target regions based on SeqCap_EZ_Exome_v3 Kit. 95% 
of the target regions had at least 10× coverage. After identification of variants, the 
synonymous variants, splice acceptor and donor site mutations, and short, frame shift 
coding insertions or deletions (indel) in neuropathy linked genes were screened. For this 
purpose we used Variant Analyser software and after filtering out synonymous SNPs, 23 
heterozygous variants remained, Further narrowing based on protein prediction scores 
and ClinVar and allele frequency data, resulted in two variations. No rare homozygous or 
compound heterozygous variants were found in the analyzed neuropathy-linked genes. 
Finally, two mutations were kept in and validated with Sanger sequencing. The POLG 




MME c.1946 T>C alteration (p.I649T) was recently described as a variant with unknown 
significance (ClinVar, rs184666602). Both amino acid changes are located in a taxonomic 
well-conserved region of the proteins and in silico analysis predicted its likely pathogenic 
nature. Only the MME alterations were present in ExAc database with an allele frequency 
of 0.00005. Based on ACMG guideline, the POLG variant is likely pathogenic alteration 
while the MME mutation was declared as variant with unknown significance.  
4.6.3 HINT1 pathogenic variant 
Target sequencing of dHMN and HMSN genes was performed in 5 female and 4 male 
patients (mean age at examination was 20.2±13.5 years and  28.25±24.9 years, 
respectively) All patients had more dominant muscle involvement than sensory 
disturbance. Three patients had delayed muscle relaxation, two CNS involvement 
(cerebellar ataxia and pyramidal sign, respectively), and one patient suffered from 
prominent scapular weakness. All the patients data were carefully checked for pathogenic 
and likely pathogenic alterations using ClinVar database, PubMed and ACMG guideline.  
The same homozygous pathogenic mutation was found in three patients (HINT1, c.110 
G>C, p.R37P, rs149782619). Three variants with unknown significance were also present 
in CMT-linked genes (HSPB8 c.233 G>T, p.R78M, rs55826713; DCTN1 p.D762N and 
ATP7A p.T818A). Based on segregation analyses, these variants were found in 
symptomless relatives as well.  
Patients, carrying HINT1 mutation, presented progressively decreasing muscle strength, 
delayed muscle relaxation, elevated CK levels, impaired mental performance,  and mild 
sensory disturbance. Age of onset ranged between 9-14 years. Interestingly, beside axonal 
neuropathy, EMG registered neuromyotonia which was characterized by prolonged 
muscle relaxation after voluntary muscle contractions, causing by the hyperexcitability 







 Table 9.  Clinical feature of HINT1 patitents. Abbr.: UL – upper limb; LL – lower 
limb, N/A – no data; ; (-) – none; (+) – mild; (++) – moderate; (+++) – severe 
  D-HINT1 (f) E-HINT1 (m) F-HINT1 (f) 





childhood), later hand 
weakness (5 ys old) 
walking on tip toe (18 
months), unable to run or 
crouch 
impaired hand dexterity, 
hyperkinesia, and paresis 




delayed, walking on tip 





++ +++ + 
Muscle tone normal normal normal 
Muscle strength 
LL: proximal and distal 
paresis (++) 
LL: proximal and distal 
paresis (++) 
LL: proximal and distal 
paresis (++); UL: distal 
paresis (+) 
Muscle atrophy LL (++) LL (++) LL (+) 
Tendon reflexes absence absence decreased 
Pyramidal sign  - - - 
Sensory 
disturbance 
+ ++ + 
Cerebellar sign - - dysdiadochokinesis 
Contractures 
symmetric contractures 
in hands and feet, 
Achilles contractures 
symmetric contractures 
in hands, elbow, and feet 
(hammer toe), Achilles 
contractures 
hyperflexible joints 
without any contractures or 
deformity 
Dystonia 
focal dystonia (writing 
cramp) 
focal dystonia (writing 
cramp) 
- 
Brain MRI normal - adenoma in the hypophysis  
Laboratory 
features 
CK: 270 U/L, LP: 0.25 
g/L 
CK: 1411-1806 U/L 
CK: 410 U/L, 
Vitamin D 11.9 ng/ml 
Neuromyotonia 
on EMG 




fascicules and COX 
negative fibers 
neurogenic featuers, 
sural biopsy shows 


















5.1 Frequency of CMT genes in Hungary 
This study is the first comprehensive genetic epidemiology study of CMT in Hungary. 
Our findings indicate, that the PMP22 alterations (40.1%) were the most frequent which 
were followed by GJB1 (9.6%), MPZ (4.5%) and MFN2 (2.4%) mutations.  Rare variants 
in EGR2, CTDP1, NDRG1, and PMP22 were found only in a small percentage of our 
cohort (3.4%). These findings mean a 59.9% success rate which is in accordance with 
other recent studies (157). The distribution of electrophysiological subtypes (158) and the 
prevalence of the most common gene alterations was also consistent with previous 
observations, but the frequencies of genetic subtypes deviate with respect to other 
epidemiological data (Table 10).  
















N=531 N=187 N=787 N=438 N=589 N=425 N=1652 
PMP22 
duplication 
39.7% (211) 19.8% (37) 36.9% (290) 42.0% (184) 35.6% (180) 39.5%(168) 37.2% (614) 
GJB1 
9.6% (51) 4.8% (9) 10.2% (80) 12.8% (56) 8.5% (43) 10.8% (46) 6.5% (107) 
MPZ 
4.5% (24) 3% (6) 5.7% (45) 4.3% (19) 4.1% (21) 3.1% (13) 4.1% (67) 
MFN2 
2.4% (13) 1.1% (2) 2.7% (21) 1.6% (6) 2.4% (12) 2.8% (12) 4.2% (70) 
EGR2 
0.8% (4) - 0.1% (1) - - 0.0% (0) 0.06% (1) 
PMP22 point 
mutation 
0.4% (2) 0% (0) 0.6% (5) 0.5 (2) 0.4% (2) 1.4% (6) 6.5% (107) 
NDRG1 (LOM) 
1.6% (8) - - 1.9% (7) 0.3% (2) - - 
CTDP1 
(CCFDN) 
0.8% (4) - - - - - - 
Cumulative hit 
rate of further 
genes 
0% (0) 0% (0) 10.8% (85) 22.1% (97) 4.5% (23) 9.2% (21) 7.3% (121) 
Number of tested 
genes 
7 7 11 22 12 13 20 
No genetic 
diagnosis 
40.3% (214) 71% (133) 36.9% (290) 15.3% (67) 43.5% (220) 37.4% (159) 39.6% (655) 
Nine novel alterations were found in the investigated patients. According to ACMG 
guidelines, the variants are pathogenic or likely pathogenic alterations. The clinical 




phenotype (MPZ p.S20P) was present in one case which was an unusual feature regarding 
this gene. 
The localization of mutant amino acids was also diverse compared to international data. 
In GJB1, the alterations of mutational hotspot codon 164 were responsible for the 14.3% 
of CMTX1 in our index patients, which is slightly lower than international findings (18-
27.8%) (162, 163). We have also found that the occurrence of pathogenic alterations in 
cytoplasmic loop domain (21.4%) was the second most frequent cause of CMTX1 in our 
cohort which domain is usually underrepresented in other CMT studies (0-14.8%) (164, 
162, 163). The p.R468H mutation of MFN2 seems to be a mutational hotspot in 
Hungarian patients. A similar high proportion of this variant (42.9%) was reported from 
Spain (81). These observations may indicate a preferred mutational and hotspot regions 
among Hungarian patients compared to other cohorts and can raise the possibility of a 
connection between ethnicity and localization of pathogenic alterations. Notably, founder 
mutations were detected in 21% of Roma patients, which draws further attention to the 
relevance of origin and targeted screening of these founder mutations in patients with 
Roma ancestors.  
5.2 Phenotypic spectrum of CMT genes in Hungarian patients 
Clinical and electrophysiological evaluation of patients along with the genetic result was 
further analyzed in order to unravel possible genotypic and phenotypic connections. 
Regarding the age of onset, the initial symptoms manifested in the first three decades of 
life in 70% of patients (mean age of 25.5 ys) where asymptomatic cases were included. 
Due to the small number of similar investigations, it proved difficult to compare disease 
severity with other studies. Fridman et al. evaluated the CMTES of 462 CMT1A cases 
and their findings indicated a slightly higher mean CMTES than our patients’ mean score  
(8.5 and 8.1, respectively) (157).  
The progression of CMT during a patient’s lifetime is well-known (165). Based on our 
data, the change in CMTES shows a linear correlation with age and disease duration, 
while the course of worsening could be estimated in the quarter of the CMT population 
with the regression line. Nevertheless, disease progression can be predicted 10-35% more 
accurately in CMT1A and CMTX1 cases. This difference may come from the fact that 




severity even with the same causative gene or in same affected family due to distinct 
genetic features of the causative genes and the different modifying factors, such as gene-
gene interactions (simultaneous presence of one or more pathogenic allele mutation load), 
epigenetic modification effects, co-morbidities (diabetic neuropathy, alcoholism, 
autoimmune disease etc.) or disease management. These all have a cumulative impact on 
disease severity leading to a less predictable course of progression (25-29). The 
combinatorial influence of these suspected factors may interact in the same biological 
pathways and affect the penetrance and/or the expressivity of the phenotype.  
Additional symptoms or diseases occurred in more than one fifth of our patients. CNS 
abnormality was the most frequently associated feature and it was present mainly with 
GJB1 (see 6.3.) and MFN2 pathogenic alterations. Both of these CMT genes were 
reported with CNS involvement occasionally resulting in diagnostic uncertainty (166, 
167, 31).  Several studies have linked PMP22 and NDRG1 gene variants to a higher 
occurrence of sensorineural hearing impairment starting in the early decades of life (96, 
168, 169) which is in accordance with our results. Interestingly, MPZ and GJB1 
pathogenic alterations have not appeared with deafness in spite of their frequent co-
occurrence (31). Our findings also suggest a higher incidence of autoimmunity in 
CMT1A. Few observations have raised the possibility of superimposed dysimmune 
mechanisms in CMT1A (170, 43) and a higher proportion of antibodies against PMP22 
has been detected in CMT1A patients (171). However, the processes of immunological 
abnormalities are still indistinct and need to be further studied for a deeper insight.  
5.3 Clinical and electrophysiological analysis of a set of CMTX1 patients 
Our clinical observations and previous CMT studies have emphasized the different 
phenotypical appearance of GJB1 pathogenic alterations between the two genders. The 
inheritance of CMTX1 is usually considered as dominant since females and males both 
have clinical symptoms; however, female are affected with a less severe neuropathy. To 
analyze this phenomenon, comparative statistical analyzes were used to investigate 
whether there are clear differences between Hungarian CMTX1 males and females. We 
found that most of the females were older at disease onset, had milder CMTNS, CMT 
examination scores and the frequency of certain additional signs and symptoms were 




had been found less affected. (61, 163).  Along with these studies, it can be presumed that 
CMTX1 is indeed an X-linked dominant disease but with an incomplete penetrance in 
females. A connection between the distribution of X inactivation and symptom severity 
in female CMTX1 patients can be a potential explanation for this phenomenon. However, 
the clinical phenotype has not shown any correlation with X inactivation pattern in blood 
according to a previous study (172). This raises the possibility that the X inactivation 
distribution may differ between Schwann cells and leukocytes.  
The clinical and electrophysiological data of other previously reported cases with same 
mutated codon pointed out intriguing similarities regarding the age of onset, type of 
neuropathy and CNS involvement. Due to the limited number of data, it is not enough to 
reflect an unambiguous conclusion but this observation draw the attention to the 
possibility that same mutation can inflict highly similar phenotype and is mildy affected 
by other factors.   
In CMTX1, the type of neuropathy frequently differs within the same family (61, 173). 
Usually, females had only amplitude reduction while males had intermediate or 
demyelinating neuropathy. Here, the electrophysiological features of neuropathy did not 
differ in the same family. Furthermore, the excessive temporal dispersion was present 
only in one case (p.M194I), while in previous electrophysiological studies it was found 
to be more frequently associated with CMTX1 and causing difficulty in distinguishing 
CMTX1 from chronic inflammatory demyelinating polyneuropathy (CIDP) (174, 175). 
In our case, based on the family history, clinical features, and laboratory data CIDP could 
be excluded (175). 
GJB1 mutations have associated with CNS involvement significantly more often than 
CMT alone (see 6.2) but CNS symptoms can evolve in female as well. The alterations of 
codon 142, 164 and 205 were previously linked to CNS symptoms 
(www.molgen.ua.ac.be/CMTMutations) while codon 13 and 89 have not been described 
with CNS symptoms to date. It is not exactly known why some mutations cause CNS 
signs and symptom and some why not. Recently, the gap junction channel function was 
studied and compared between PNS and PNS+CNS mutants (CNS symptoms were absent 
or present, respectively). Interestingly, gap junction function was spared or slightly 




to complete loss of homotypic channels (68). Moreover, the penetrance of symptoms 
differs widely between female CMTX1 patients which also might connect to the type of 
protein dysfunction. Clinical observations also presumed the effect of domain localization 
of mutations. Highly conserved cysteine rich regions seem to be attached to more severe 
disease burdens and CNS involvement whereas mutations in CL loop refers to a more 
benign clinical picture (176); however, Shy et al confuted this hypothesis (67).  
5.4 Rare variants identified with high-throughput methods 
To further analyze the unsolved CMT2 cases, we applied high-throughput method for 
screening of pathogenic or possible pathogenic alterations. We identified pathogenic or 
likely pathogenic mutations in one third of patients. Based on the experience of other 
research groups, between a 31-46% success rate was expected with NGS methodology 
(177, 178). Our rate of 35.5% fits in the middle range but lower than our results with 
standard methodologies. 
A pathogenic TRPV4 variant was found in a two and half -year-old girl. This mutation 
affects the intracellular N-terminal ankyring domain of the TRPV4 causing the altered 
function of the ion channel and leading not only to CMT2C but to scapuloperoneal spinal 
muscular atrophy (SPSMA), congential distal spinal muscular atrophy (CDPSMA) and 
autosomal dominant skeletal dysplasias (179, 180). Clinical appearance also frequently 
associates with vocal cord palsy and respiratory distress due to diaphragm weakness 
(181). The identified p.R269H variant was already reported multiple times with SPSMA 
phenotype. Interestingly,  diverse severity of clinical picture was observed even with 
same mutation and  in same family. Biasini et al have found that the index patient’s father 
had much milder muscular weakness than his son whose phenotype was characterized by 
progressive scapuloperoneal atrophy and weakness as well as bilater congenital clubfoot 
(182). Zimon et al also found this alteration in association with SPSMA, skeletal dysplasia 
and vocal cord paresis (181). Overlapping CMT2 and SPSMA phenotype was also 
described in Greece with a p.R232C mutation. Our patient had a predominantly motor 
neuropathy with spared motor functions in scapular muscles. No major skeletal dysplasia, 
vocal cord palsy and respiratory distress was present. Most likely, similarly to the Greek 




However, taking her young age into consideration, the clinical picture can rapidly change 
therefore longitudinal follow-up is especially required in this case.  
We identified two distinct non-synonym mutations of MME and POLG genes in one CMT 
patient. POLG has a crucial role in maintaining the integrity of mitochondrial DNA and 
in mitochondrial replication. The identified p.A1082T mutation is located in the highly 
conserved polymerase domain causing altered protein features and splice site changes. 
Several pathogenic mutations were already described in this protein region. POLG does 
not belong traditionally to CMT genes, despite the fact, that it is usually associated with 
axonal neuropathy. POLG can cause a wide range of disorders including progressive 
external ophtalmoplegia with mitochondrial deletions (PEO), mitochondrial recessive 
ataxia syndrome (MIRAS), sensory ataxia with neuropathy, dysarthria and 
ophtalmoplegia (SANDO), Alpers syndrome, mitochondrial neurogastroinstinal 
encephalopathy (MNGIE), Parkinson disease, dementia and other psychiatric disorders 
(183). It worth to note that the patient does not have further comorbidities. Mitochondrial 
DNA deletion was also found which is a sensitive marker of mutated POLG protein 
further prove the pathogenicity of this alteration. 
MME encodes the metalloendopeptidase neprilysin. The identified p.I649T amino acid 
change is presumably a non-conservative alteration, which is likely to impact secondary 
protein structure resulting in impaired functions. In silico analysis predicted its damaging 
nature as well. MME mutations were first described with autosomal recessive inheritance 
(184) but Auer-Grumbach et al reported that MME also inherits dominantly causing a 
late-onset neuropathy (185). Autosomal dominant MME mutations were also linked to 
spinocerebellar ataxia (186). Interestingly, AD inheritance has an age-related incomplete 
penetrance and its patomechanism is tightly linked to reduced tissue neprilysin activity. 
The MME coded neprilysin is dedicated to degrading neuron-specific proteins including 
amyloid ß (Aß). Dysfunctioning Aß, among others, is involved in impaired mitochondrial 
dynamics, transport and Ca2+ homeostasis in neuronal cells (187). Since heterozygous 
MME mutations are linked to age-dependent penetrance, it has presumably no primary 
causative role but may modify the effect of POLG through shared functional pathways in 
mitochondrial dynamics it further worsens the mitochondrial dysfunction. Gonzaga-
Jauregui et al described a similar phenomenon regarding the effect of mutation load. They 




CMT genes versus healthy controls and suggested that genetic burden influences the 
phenotypic variability of CMT (188). The accumulation of Aß and POLG mutations 
together may cumulate the chance of Alzheimer dementia in this patient (189, 190). 
Loss of funtion mutations of HINT1 were first described in 2012 by Zimon et al in a set 
of patients with hereditary axonal neuropathy and neuromyotonia. HINT1 is a 
homodimeric purine phosphoramidase that is expressed  ubiquitously in different cells 
and participates in different apoptotic pathways, transcriptional suppression and RNA 
metabolism where interact and share common pathways with causal genes of  CMT 
(AARS, GARS, HARS, KARS, MARS, YARS) (191). HINT1 mutations might take effect in 
three different ways: alter residues critical for the catalytic activity; lead to nonsense-
mediated decay of the faulty transcript; or cause instabil protein and subsequent 
proteasome-mediated degradation (191). Interestingley, Mice lacking Hint1 proved to be 
less useful for investigating HINT1-associated neurodegeneration since they showed 
normal motor performance test results without any signs of nerve degeneration (192). 
To date, the homozygous p.R37P amino acid change proved to be the most frequent 
pathogenic alteration of HINT1. Since it was found almost exlusively in in Central-
European countries and Turkey, it is considered to be a founder mutation but more data 
is required to validate that hypothesis (193). HINT1 mutations are associated with a more 
prominent motor involvement than sensory. Clinical phenotype of patients frequently 
included gait disturbances, cramps, contractures, foot deformity, elevated CK level and 
sensory loss (194). 
HINT1 is also expressed in the central nervous system implicating further effects on the 
CNS (195). Previous studies found that patients suffering from major depression disorder 
had an increased level of HINT1 protein in dorsolateral prefrontal cortex, and, on the 
contrary, schizophrenic patients had decreased level of protein. These phenomenon may 
explain the detected psychiatric disorders of the probands (196). 





Regarding the aims of the study, the current research established following novelties and 
conclusions: 
1. In Hungary, we have conducted the first genetic epidemiology study of CMT. 
Analysis of the most common CMT genes in Hungarian patients has revealed the 
genetic etiology almost in 60% of cases which is a satisfactory result compared to 
international findings. Our data also enhance the importance of ethnicity since 
certain minorities frequently carry founder mutations and certain mutational 
hotspot regions seems to be overrepresented in Hungarian patients. Based on that, 
the screening of frequent alterations should precede other gene tests in selected 
cases.  
2. We identified nine novel pathogenic or likely pathogenic variants of GJB1, EGR2 
and MPZ genes. The detailed clinical phenotypes of patients harboring 
presumably disease causing alterations further broaden the accessible data which 
help in the further understand of distinct molecular patomechanisms and facilitate 
the research of new pharmaceutical agents. 
3. In general, the applied prediction models of disease progression was less effective; 
however, the accuracy was higher if same genetic subtypes were analyzed. Our 
findings indicate that the genetic diagnosis is a strong predictor but family history, 
associated diseases, environmental factors and further genetic alterations was not 
included in this model. Further researches should also consider and study these 
factors in developing of a more precise prediction model.  
4. Fifth of the patients have shown one or more non-conventional CMT symptoms 
or associated diseases. Central nervous system involvement was significantly 
more frequent with GJB1 and MFN2 mutations while dysimmune mechanisms 
and hearing impairment was associatied more commonly with PMP22 
duplication. Based on that observations, certain features can help in determining 
the most likely genes which can facilitate the diagnostic algorithm of CMT along 
with the family history. Our findings also broaden the spectrum of known GJB1 
and MFN2 codons involved in CNS abnormalities. 
5. Female GJB1 patients had less severe phenotype and later age of onset than males 




frequent CNS involvement. These difference clearly highlight the importance of 
precise a pedigree and deep phenotyping calling attention on CMTX1 patients in 
an extremely heterogenous disease group and further enhancing the cost-effective 
diagnostics of CMT. 
6. New generation sequence platforms can be a robust diagnostic tool to unwrap 
sporadic cases and study overlapping syndromes. Cases, where traditional genetic 
analyses have not confirmed the pathogenic variant, new approach have lead to a 
genetic diagnosis in multiple cases. Here, we also determined a possibly frequent 
HINT1 pathogenic alteration which analysis should be inserted into the CMT 
diagnostic workflow in Hungary, especially in cases, where predominantly axonal 






A Charcot-Marie-Tooth betegség egy örökletes, progesszív lefolyású neuromuscularis 
megbetegedés, mely körülbelül 3500-4500 beteget érint Magyarországon. A CMT 
diagnosztikájában bekövetkezett változások az elmúlt években a diagnózist gyorsabbá, 
pontosabbá és elérhetőbbé tette. Számos klinikai vizsgálat hívta fel korábban a a 
figyelmet arra, hogy a jól fenotipizált kohorszokban, bizonyos faktorok figyelembe 
vételével növelhető a diagnosztikus hatékonyság. Jelen értekezés célja, hogy 
megvizsgálja a magyarországi CMT betegek genetikai hátterét, és információt nyerjen a 
betegség klinikai variabilitásáról egyes gének esetében. Ebből a célból 409 CMT1-ben és 
122 CMT2-ben szenvedő betegnél vizsgáltuk meg rutinszerűen a PMP22, GJB1, MPZ, 
EGR2 és MFN2 géneket, míg az NDRG1 and CTDP1 gének alapító mutációit roma 
betegeknél szűrtük. A CMT2 betegcsoport 15 betegének esetében újgenerációs 
szekvenátor platform segítségével vizsgáltuk a minor CMT gének érintettségét. A CMT1-
es betegek 67.2%-nál, a CMT2 kohorsz 33.6%-nál sikerült genetikai diagnózist 
felállítani. A leggyakoribb érintett gén a PMP22 (40.5%) volt, melyet a GJB1 (9.2%), 
MPZ (4.5%), MFN2 (2.5%), NDRG1 (1.5%), EGR2 (1%) and CTDP1 (0.8%) patogén 
eltérései követtek. Az újgenerációs szekvenátor platformon történt vizsgálat során a 
HINT1 gén alapító mutációját homozigóta formában három gyermeknél azonosítottuk 
panel szekvenálással, míg teljes exom analízis során egy TRPV4 mutációt és egy 
feltételezetten patogén POLG variánst találtunk. A négy leggyakoribb gén vizsgálata az 
esetek 50%-ban azonosította a genetikai eltérést, míg a teljes kohorszt figyelembe véve a 
sikerességi ráta 59.9% volt a hagyományos metodikák alkalmazásával. A klinikai kép és 
a betegség súlyossága nagy variabilitást mutatott a betegeknél. Mintegy ötödüknél az 
örökletes neuropathia atípusos tünetekkel és társbetegségekkel szövődött, melyek több 
esetben is szignifikáns összefüggést mutattak egyes génekkel. A CMTX1 betegeknél a 
betegség súlyossága enyhébb volt a női pácienseknél. Az újgenerációs szekvenátor 
platformon végzett vizsgálatok a HINT1 gén magas előfordulási gyakoriságára hívja fel 
a figyelmet a gyakran neuromyotoniával szövődött, korai kezdetű örökletes 
neuropathiánál. Jelen értekezésben közölt eredmények hasznosnak bizonyulhatnak egy 
általános vizsgálati stratégia felállításában magyarországi CMT betegek esetében, 
valamint az örökletes neuropathiák klinikai heterogenitásáról rendelkező tudásunkat is 





Charcot-Marie-Tooth disease is a progressive, inherited neuromuscular disorder which 
may affect around 3500-4500 Hungarian patients. In the last decades, the genetic research 
of CMT made the diagnostics more successful and accessible than ever been. It has been 
also recognized that well-characterized populations and gene specific epidemiological 
data along with other factors can enhance the efficiency and lower the costs of 
diagnostics. This thesis aims to investigate Hungarian patients suffering from inherited 
neuropathy and unravel the genetic cause of the disease and assess the phenotypical 
variability and spectrum of different causative genes. Here we investigated 409 CMT1 
and 122 CMT2 patients. The genetic testing of PMP22, GJB1, MPZ, EGR2 and MFN2 
genes were performed routinely while NDRG1 and CTDP1 genes were screened only for 
founder mutations in Roma patients. In a small subset of CMT2 patients, new generation 
sequencing was applied to identify CMT genes with minor frequencies. 67.2% of the 
CMT1 and 33.6% of the CMT2 patients received a genetic diagnosis which indicates a 
59.9% success rate in the study population. Considering all the affected individuals, the 
most frequent gene was the PMP22 (40.5%) which was followed by the GJB1 (9.2%), 
MPZ (4.5%), MFN2 (2.5%), NDRG1 (1.5%), EGR2 (1%) and CTDP1 (0.8%) pathogenic 
alterations. NGS target sequencing found HINT1 homozygous founder mutations in three 
minor patients while whole exom sequencing revealed a pathogenic TRPV4 alteration and 
a likely pathogenic POLG variant. The screening of the four most common causative 
genes resulted in the genetic diagnosis in more than the half of the cases and the result 
indicates a 59.9% overall success rate. The phenotypic spectrum and the disease severity 
of the studied patients also varied broadly. Fifth of the patients shown additional signs 
and symptoms and some features were tightly associated with certain genes. Regarding 
the CMTX1 patients female had a milder clinical appearance than males. NGS results 
also highlighted  the high frequency of HINT1 gene in Hungarian patients with early onset 
and neuromyotonia. Current results provide handful data to design a general diagnostic 
scheme of CMT in Hungary and deepen the current knowledge about the clinical 
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12. Supplement  
 
Supplement 1 - Genetic classification of Charcot-Marie-Tooth and related 
neuropathies. OMIM database and the Neuromuscular Database of Washington 
University has been used for this compilation.  
Abbreviations: Inher. – Inheritance, AD – autosomal dominant; AR – autosomal 









Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 
diseases of the 
gene * 
                  






17p12 AD 1991 myelin protein 
early onset, pupil. abn., optic neuritis, 
nystagmus, facial and bulbar nerve weakness, 
vocal cord palsy, deafness, CNS inv., UMN 
sign, MRI abn., cognitive imp., diaphragmal 








Myelin protein zero 1q22-q23 AD 1993 myelin protein 
early onset, pupil. abn., bulbar and facial 
weakness, vocal cord palsy, MRI abn., 
cognitive imp., ANS inv., tremor, scoliosis, 







induced tumor necrosis 







early onset, deafness, cognitive impairment, 








Early growth factor 2 10q21.3 AD 1998 
transcriptional 
regulation 
early onset, nystagmus, opthalmoparesis, 
bulbar and facial weakness, vocal cord palsy, 















light chain  
8p21.2 AD 2000 cytoskeleton 
early onset , nystagmus, bulbar and facial 
weakness, deafness, UMN inv., MR abn., ANS 











Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 
diseases of the 
gene * 
                  
















Mitofusin 2 1p36.2 AD/AR 2004 
mitochondrial 
dynamics 
early onset, pupil. abn., nystagmus, ophtalmo- 
paresis, optic atrophy, facial and bulbar weakness, 
vocal cord palsy, CNS and UMN inv., spasticity, 
MR abn., cognitive imp., tremor, scoliosis, ANS 







3q21.3 AD 2000 
intracellular 
transport  
more prominent sensory symptoms, scoliosis,  






















19q13.33 AR 2009 
transcriptional 
regulation 






channel subfamily V 
member 4 
12q24.11 AD 2010 ion channel 
vocal cord palsy, early onset, tremor, skeletal 
abnormalities, contractures, deafness, bulbar signs, 
tremor, facial and progressive paresis, strabismus, 







protein heavy chain 








7p14.3 AD 2003 
protein 
biosynthesis 










Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 






protein light chain  
8p21.2 AD 2000 
necleosceleton, 
cytosceleton 
early onset, more prominent sensory symptoms, 
scoliosis,  contractures, deafness, cognitive 
impairment, UMN signs, chronic vomiting, 






Heat shock protein 
B1 
7q11.23 AD 2004 chaperone 
more prominent motor symptoms, hand 
deformities, fasciculation, pain,  
dHMN IIB 
CMT2G - - 
12q12-
q13.3  
AD 2004 - - - 
CMT2G             




TRK-fused gene 3q12.2 AD 2012 - 
tremor, deafness, UMN and bulbar signs, facial 
weakness, proximal> distal muscle paresis, 






Myelin Protein Zero 1q22-q23 AD 1993 myelin protein see above (CMT1B) - 











8p21.11 AD 2002 
mitochondrial 
dynamics 
early onset, vocal cord palsy, scoliosis, hand 
deformities, skeletal deformities, bulbar signs, 
facial weakenss, pain, optic atrophy, respiratory 





Heat shock protein 
B8 




Dynamin 2 19p13.2 AD 2005 
mitochondrial 
dynamics 
early onset, facial weakness, cataract, 
ophtalmoparesis,  mtDNA deletion cognitive imp., 
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Associated 


















14q32.31   AD 2011 
axonal 
transport 
early onset, prominent proximal muscle weakness, 





























containing protein 2 
4q31.3 AR 2013 
protein 
degradation 







11q13.3 AR 2014 
transcriptional 
regulation 
more prominent muscular paresis 





Heat shock protein 
DNAJ-like 1 
2q35 AD 2016 chaperone - 




















12q13.3 AD 2013 
protein 
biosynthesis 
Pain, proximal=distal weakness 
Interstitial lung 










Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 


















5q31.3 AD 2015 
protein 
biosynthesis 














MORC family CW 
type zync finger 
protein 




                  
I-CMT - Autosomal dominant and recessive intermediate HMSN     
DI-CMTA - - 
10q24.1-
q25.1  




Dynamin 2 19p13.2 AD 2005 
mitochondrial 
dynamics 



















Inverted formin 2 14q32.33 AD 2011 cytosceleton 
early onset, tremor,scoliosis, hand deformities, 
FSGS, deafness, cognitive imp., pain, enlarged 











Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 






binding protein beta 
4 











8p21.11 AR 2002 
mitochondrial 
dynamics 






16q23.1 AR 2010 
protein 
biosynthesis 






protein, fam. G 
member  5 
1p36.31 AR 2013 
Rho GTPase 
signalling 





oxidase subunit VIA 
polyptide 1 




                  
CMT4 -Autosomal recessive demyelinating hereditary motor and sensory 
neuropathy 







8p21.11 AR 2002 
mitochondrial 
dynamics 





protein 2  
11q21 AR 2000 
phosphoinositide 
metabolism 
early onset, more prominent proximal 
weakness, vocal cord palsy, scolisosis, hand 
deformities, bulbar signs, faical weakness, 






Set binding factor 2 11p15.4 AR 2009 
phosphoinositide 
metabolism 
early onset, scoliosis, hand deformities, 











Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 





Set binding factor 1 22q13.33 AR 2013 
phosphoinositide 
metabolism 
microcephaly and cognitive impairment, scoliosis, 
strabismus, ophthalmoplegia, facial weakness, 
variable syndactyly of the hands and feet, 





SH3 domain and 
tetratricopeptide 
repeat domain 2 
5q32 AR 2003 
intracellular 
transport 
proximal weakness, cranial nerve involvement, 
deafness, scoliosis, slow pupillary light reflexes, 
and lingual fasciculations, spine deformities, 
respiratory weakness 
mono-









8p21.11 AR 2002 
intracellular 
transport 
 early onset, vocal cord palsy, deafness, scoliosis, 






Early growth   factor 
2 / Myelin Protein 
Zero  




















Hexokinase 1 10q22.1 AR 2009 
energy 
production 






Fyve, RhoGEF and 
pH domain-
containing protein 4 
12p11.21 AR 2007 
Rho GTPase 
signalling 
early onset, more prominent sensory symptoms, 








6q21 AR 2007 
phosphoinositide 
metabolism 
early onset, more prominent proximal weakenss, 
tremor, scoliosis, hand deformity, facial weakness,  
cranial nerve involvement, respiratory failure, 






Surfeit 1 9q34.2 AR 2013 
energy 
production 
scoliosis, deafness, nystagmus, cerebellar ataxia, 
T2 hyperintense lesions in putamen and 
periaquaductal, lactic acidosis 
Leigh syndrome 












Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 
diseases of the 
gene * 
                  




Gap junction beta 1 X13.1 XLD 1993 
intracellular 
transport 
CNS involvement, pyramidal signs, sensorineural 
hearing loss, early onset, conduction block 
- 
CMTX2 - - Xp22.2  XLR - - - - 



















































Xq22.1 XLR 2015 
cytoskeletal 
protein 











Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 
diseases of the 
gene * 
                  






chain subunit 1 










chain subunit 2 







Atlastin GTPase 1 14q22.1 AD 2011 
ER membrane 
shaping 






19p13.2 AD 2013 
transcriptional 
regulation 








sterile 20-like kinase 










134 member B 

















protein type 9 
subunit alpha 




Inhibitor of kappa 
light polypeptide 
gene enchancer in 
B-cells 














Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 






kinase receptor 1 































voltage gated type 
XI alpha subunit 


























heavy chain type 1 




Heat shock protein 
B8 




Heat shock protein 
B1 




Heat shock protein 
B3 




F box only protein 
38 




dHMN III - - 11q13 AR - - - - 
dHMN IV - - 11q13 AR - - 













Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 
















2p11.2 AD 2012 
intracellular 
transport 





















11q13.3 AR 2014 
transcriptional 
regulation 






Solute carrier family 
5, member 7 
2q12.3 AD 2012 
intracellular 
transport 




Dynactin 1 2p13.1 AD 2003 
axonal  
transport 








channel subfamily V 
member 4 
12q24.11 AD 2010 ion channel see above (CMT2C) 
CMT2C, 
dwarfism 
dSMA2 - - 9p21 AR - - 
cortical tract involvement, patients originating 
from the Jerash region of Jordan 
- 




Heat shock protein 
DNAJ-like 1 







11q13.3 AR 2014 
regulation of 
transcription 














Gene name Locus Inh. Year Function Associated features to the neuropathy 
Associated 
diseases of the 
gene * 
SMARD2 LAS1L 
LAS1 like ribosome 
biogenesis factor 
Xq12 XLR 2014 
ribosome 
biosynthesis 

















Bicaudal D homolog 
of 2 
9q22.31 AD 2013 
cytosceletal 
protein 
severe distal weakness, UMN abn., brisk reflexes HSP 








mtDNA mat. 2012 
energy 
production 





mtDNA mat. 2013 
energy 
production 
episodic weakness - 
Special forms of hereditary neuropathies             




Gap junction Beta 3 1p34 n/a 2001 
intracellulare 
transport 
sensorineural hearing loss 
erythro- 
keratodermia 







5p15.2 AR 2006 chaperone - HSP 
HMSN + ataxia IFRD1 
Interferon-related 
developmental 
regulator gene 1 
7q31.1 AD   
transcriptional 
regulation 





of RNA polymerase 
II subunit A, 
phosphatase of, 
subunit 1 
18q23 AR 1999 
protein 
biosynthesis 
congenital cataracta, facial dysmorphisms, 
nystagmus, short stature, kyphoscoliosis, mental 












Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 





Tubulin beta 3 16q24 AD 2010 
transcriptional 
regulation 
fibrosis of extraocular muscles, cortical dysplasia  - 





16q23.2 AR 2000 
cytosceletal 
protein  
gaint axons, kinky red hair, cerebellar ataxia, 
spastic paraparesis, pyramidal signs, facial 
diplegia, lower IQ, minor clinical signs 
- 





























8p23.3 AD 1998 
Rho GTPase 
signalling 
demyelinating polyneuropathy - 







10p13 AR 1997 
metabolic 
process 
night blinding, iris atrophy, cataract, ataxia, 

















Peroxin 1 7q21.2 AR 2002 
peroxisome 
biogenesis 
deafness, retinitis pigmentosa, hepatomegaly, 















Gene name Locus Inh. Year Function Associated features to the neuropathy  
Associated 








20p11.21 AR 2010 
metabolic 
process 
PHARC: Polyneuropathy, Hearing loss, Ataxia, 













aortic aneurysma, bronchiectasia, arthropathy, 
increased elasticity of skin 
- 





Solute carrier family 
12, member 6 














14q31.3 AR 1994 
metabolic 
process 
In childhood: mental retardation, excessive crying, 
optic atrophy, spasticity;  in adulthood: spastisity, 









mtDNA mat. 1990 
energy 
production 
pronounced motor neuropathy, CNS involvement, 









 14q32.11 AR 2002 
DNA complex 
repair 







protein 1  
















Parameter 0 1 2 3 4 
Sensory symptoms None 
Symptoms below or at 
ankle bones 
Symptoms up to 
the distal half of 
the calf 
Symptoms up to 
the proximal half of 
the calf, including 
knee 
Symptoms above knee 





Trips, catches toes, 
slaps feet Shoe inserts 










Mild difficulty with 
buttons 
Severe difficulty 
or unable to do 
buttons 
unable to cut most 
foods 
Proximal weakness (affect 
movements involving the 
elbow and above) 
Pinprick sensibility Normal 
Decreased below or at 
ankle bones 
Decreased up to 
the distal half of 
the calf 
Decreased up to the 
proximal half ofthe 
calf, including knee 
Decreased above knee 
(above the top ofthe 
patella) 
Vibration Normal Reduced at great toe Reduced at ankle 
Reduced at knee 
(tibial tuberosity) 
Absent at knee and ankle 
Strength (legs) Normal 
4+, 4, or 4— on foot 
dorsiflexion or plantar 
flexion 
<3 on foot 
dorsiflexion or 
<3 on foot 
plantar flexion 
<3 on foot 
dorsiflexion and <3 
on plantar flexion 
Proximal weakness 
Strength (arms) Normal 
4+, 4, or 4— on 
intrinsic hand muscles** 
<3 on intrinsic 
hand muscles** 
<5 on wrist 
extensors 
Weak above elbow 
ulnar CMAP >6 mV 4-5.9 mV 2-3.9 mV 0.1 -1.9 mV Absent 








Supplement 3: Neuropathy gene list for NGS screening. 
PMP22, MPZ, LITAF, EGR2, PMP22, NEFL, KIF1B, MFN2, RAB7, LMNA, MED25, 
TRPV4, NEFH, GARS, NEFL, HSPB1, TFG, MPZ, GDAP1, HSPB8, DNM2, AARS, 
DNCH1, LRSAM1, DHTKD1, TRIM2, IGHMBP2, DNAJB2, MME, MARS, NAGLU, 
HARS, SPG11, MORC2, DNM2, YARS, MPZ, IFN2, GNB4, GDAP1, KARS, 
PLEKHG5, COX6A1, MTMR2, SBF2, SBF1, SH3TC2, NDRG1, PRX, HK1, FGD4, 
FIG4, SURF1, AIFM1, PRPS1, PDK3, DRP2, SPTLC1, SPTLC2, ATL1, DNMT1, 
WNK1, FAM134B, KIF1A, SCN9A, IKBKAP NTRK1, NGFB, DST, SCN11A, POLG, 
OPA1, MFN1, DNMT2, ATX2, PIEZO2, DYNC1H1, HSPB8, HSPB1, HSPB3, 
FBXO38, REEP1, BSCL2, IGHMBP2, SLC5A7, DCTN1, TRPV4, LAS1L, APT7A, 
BICD2, mtATP6, mtATP8, GJB3, CCT5 IFRD1, CTDP1, TUBB3, GAN1, DCAF8, 
SOX10, HINT1, ARHGEF10, PHYH, PEX7, PEX1, MICU1, ABHD12, EMILIN1, 
KCC3 ARSA, GALC, MT-ATP6, TDP1, SETX, SCO2, TRIM2, GALC 
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